CN117447466A - Oxazole compound and preparation method and application thereof - Google Patents
Oxazole compound and preparation method and application thereof Download PDFInfo
- Publication number
- CN117447466A CN117447466A CN202210851738.3A CN202210851738A CN117447466A CN 117447466 A CN117447466 A CN 117447466A CN 202210851738 A CN202210851738 A CN 202210851738A CN 117447466 A CN117447466 A CN 117447466A
- Authority
- CN
- China
- Prior art keywords
- compound
- nhc
- alkyl
- room temperature
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 Oxazole compound Chemical class 0.000 title claims abstract description 96
- 238000002360 preparation method Methods 0.000 title claims abstract description 33
- 150000001875 compounds Chemical class 0.000 claims abstract description 234
- 150000003839 salts Chemical class 0.000 claims abstract description 23
- 239000012453 solvate Substances 0.000 claims abstract description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 16
- 201000010099 disease Diseases 0.000 claims abstract description 14
- 239000003814 drug Substances 0.000 claims abstract description 14
- 230000001404 mediated effect Effects 0.000 claims abstract description 12
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims abstract description 8
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 177
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 91
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 87
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 79
- 239000000243 solution Substances 0.000 claims description 74
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 50
- 238000000034 method Methods 0.000 claims description 48
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 33
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 32
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 30
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 30
- 229910052736 halogen Inorganic materials 0.000 claims description 29
- 150000002367 halogens Chemical group 0.000 claims description 29
- 239000007821 HATU Substances 0.000 claims description 25
- 238000011282 treatment Methods 0.000 claims description 24
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 23
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 20
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 18
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 17
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 claims description 17
- 125000000217 alkyl group Chemical group 0.000 claims description 17
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 17
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 17
- 238000007112 amidation reaction Methods 0.000 claims description 16
- 238000006243 chemical reaction Methods 0.000 claims description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims description 16
- 125000001072 heteroaryl group Chemical group 0.000 claims description 14
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 14
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 12
- 206010060862 Prostate cancer Diseases 0.000 claims description 12
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 12
- 125000003118 aryl group Chemical group 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 12
- 229910052805 deuterium Inorganic materials 0.000 claims description 12
- 229910052757 nitrogen Inorganic materials 0.000 claims description 12
- 239000012321 sodium triacetoxyborohydride Substances 0.000 claims description 12
- 238000001308 synthesis method Methods 0.000 claims description 12
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 11
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 10
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 9
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 9
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 9
- 125000005842 heteroatom Chemical group 0.000 claims description 9
- 239000012280 lithium aluminium hydride Substances 0.000 claims description 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 8
- 229910052760 oxygen Inorganic materials 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 8
- 238000001816 cooling Methods 0.000 claims description 7
- 229910052717 sulfur Inorganic materials 0.000 claims description 7
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 7
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 6
- IZDROVVXIHRYMH-UHFFFAOYSA-N methanesulfonic anhydride Chemical compound CS(=O)(=O)OS(C)(=O)=O IZDROVVXIHRYMH-UHFFFAOYSA-N 0.000 claims description 6
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 claims description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 125000001424 substituent group Chemical group 0.000 claims description 5
- MCTWTZJPVLRJOU-UHFFFAOYSA-N 1-methyl-1H-imidazole Chemical compound CN1C=CN=C1 MCTWTZJPVLRJOU-UHFFFAOYSA-N 0.000 claims description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 4
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 4
- 239000002246 antineoplastic agent Substances 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 230000003301 hydrolyzing effect Effects 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 4
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 claims description 3
- XXDAXUSYDPWTPK-UHFFFAOYSA-N 2-(oxo-lambda5-phosphanylidyne)acetic acid Chemical compound P(=O)#CC(=O)O XXDAXUSYDPWTPK-UHFFFAOYSA-N 0.000 claims description 3
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims description 3
- 125000002393 azetidinyl group Chemical group 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 125000000623 heterocyclic group Chemical group 0.000 claims description 3
- COQRGFWWJBEXRC-UHFFFAOYSA-N hydron;methyl 2-aminoacetate;chloride Chemical compound Cl.COC(=O)CN COQRGFWWJBEXRC-UHFFFAOYSA-N 0.000 claims description 3
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 239000012312 sodium hydride Substances 0.000 claims description 3
- 229910000104 sodium hydride Inorganic materials 0.000 claims description 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 2
- VHCSBTPOPKFYIU-UHFFFAOYSA-N 2-chloroethanesulfonyl chloride Chemical compound ClCCS(Cl)(=O)=O VHCSBTPOPKFYIU-UHFFFAOYSA-N 0.000 claims description 2
- MCFBUIIRFZBRCU-UHFFFAOYSA-N 4-[1-[5-[6-(trifluoromethyl)-1h-benzimidazol-2-yl]pyridin-2-yl]piperidin-4-yl]oxycyclohexane-1-carboxylic acid Chemical compound C1CC(C(=O)O)CCC1OC1CCN(C=2N=CC(=CC=2)C=2NC3=CC(=CC=C3N=2)C(F)(F)F)CC1 MCFBUIIRFZBRCU-UHFFFAOYSA-N 0.000 claims description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims description 2
- 206010003571 Astrocytoma Diseases 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010014733 Endometrial cancer Diseases 0.000 claims description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 208000032612 Glial tumor Diseases 0.000 claims description 2
- 206010018338 Glioma Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010027406 Mesothelioma Diseases 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 206010029260 Neuroblastoma Diseases 0.000 claims description 2
- JWIPGAFCGUDKEY-UHFFFAOYSA-L O[Cr](Cl)(=O)=O.C1=CC=NC=C1 Chemical compound O[Cr](Cl)(=O)=O.C1=CC=NC=C1 JWIPGAFCGUDKEY-UHFFFAOYSA-L 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 2
- 208000008938 Rhabdoid tumor Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 239000000908 ammonium hydroxide Substances 0.000 claims description 2
- 230000007131 anti Alzheimer effect Effects 0.000 claims description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- 201000009036 biliary tract cancer Diseases 0.000 claims description 2
- 208000020790 biliary tract neoplasm Diseases 0.000 claims description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 claims description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 claims description 2
- 239000003054 catalyst Substances 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims description 2
- 208000023965 endometrium neoplasm Diseases 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 208000005017 glioblastoma Diseases 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 2
- 239000002955 immunomodulating agent Substances 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 208000007538 neurilemmoma Diseases 0.000 claims description 2
- 201000008968 osteosarcoma Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 206010039667 schwannoma Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 229940121354 immunomodulator Drugs 0.000 claims 1
- 230000002584 immunomodulator Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000015556 catabolic process Effects 0.000 abstract description 33
- 238000006731 degradation reaction Methods 0.000 abstract description 33
- 206010028980 Neoplasm Diseases 0.000 abstract description 7
- 229940079593 drug Drugs 0.000 abstract description 6
- 208000024891 symptom Diseases 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 70
- 239000000203 mixture Substances 0.000 description 69
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 61
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 54
- 238000005481 NMR spectroscopy Methods 0.000 description 53
- 239000012043 crude product Substances 0.000 description 50
- 239000007787 solid Substances 0.000 description 50
- 102100024457 Cyclin-dependent kinase 9 Human genes 0.000 description 42
- 101000980930 Homo sapiens Cyclin-dependent kinase 9 Proteins 0.000 description 41
- OUSFTKFNBAZUKL-UHFFFAOYSA-N N-(5-{[(5-tert-butyl-1,3-oxazol-2-yl)methyl]sulfanyl}-1,3-thiazol-2-yl)piperidine-4-carboxamide Chemical compound O1C(C(C)(C)C)=CN=C1CSC(S1)=CN=C1NC(=O)C1CCNCC1 OUSFTKFNBAZUKL-UHFFFAOYSA-N 0.000 description 40
- 239000012267 brine Substances 0.000 description 34
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 34
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 33
- 239000012074 organic phase Substances 0.000 description 30
- 108090000623 proteins and genes Proteins 0.000 description 30
- 239000011780 sodium chloride Substances 0.000 description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 26
- 239000000741 silica gel Substances 0.000 description 26
- 229910002027 silica gel Inorganic materials 0.000 description 26
- 238000003818 flash chromatography Methods 0.000 description 24
- 230000000694 effects Effects 0.000 description 23
- 102000004169 proteins and genes Human genes 0.000 description 22
- 102000002435 Cyclin T Human genes 0.000 description 21
- 108010068106 Cyclin T Proteins 0.000 description 21
- 239000011734 sodium Substances 0.000 description 17
- 108091007914 CDKs Proteins 0.000 description 16
- 239000000543 intermediate Substances 0.000 description 16
- 235000018102 proteins Nutrition 0.000 description 14
- 239000002904 solvent Substances 0.000 description 14
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 13
- 235000019441 ethanol Nutrition 0.000 description 13
- 239000003112 inhibitor Substances 0.000 description 13
- 239000002609 medium Substances 0.000 description 13
- 239000004480 active ingredient Substances 0.000 description 12
- 108090000266 Cyclin-dependent kinases Proteins 0.000 description 11
- 102000003903 Cyclin-dependent kinases Human genes 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 11
- 238000000746 purification Methods 0.000 description 11
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 10
- 230000006907 apoptotic process Effects 0.000 description 10
- 239000012071 phase Substances 0.000 description 10
- 238000005160 1H NMR spectroscopy Methods 0.000 description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 230000022131 cell cycle Effects 0.000 description 9
- 238000012512 characterization method Methods 0.000 description 9
- 239000003921 oil Substances 0.000 description 9
- 235000019198 oils Nutrition 0.000 description 9
- 239000012467 final product Substances 0.000 description 8
- 239000013067 intermediate product Substances 0.000 description 8
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 8
- 238000006467 substitution reaction Methods 0.000 description 8
- 102000016736 Cyclin Human genes 0.000 description 7
- 108050006400 Cyclin Proteins 0.000 description 7
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 7
- 239000008380 degradant Substances 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 7
- 150000003384 small molecules Chemical class 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- 238000001262 western blot Methods 0.000 description 7
- LUGZUJZYTRPEDY-UHFFFAOYSA-N 5-tert-butyl-2-(chloromethyl)-1,3-oxazole Chemical compound CC(C)(C)C1=CN=C(CCl)O1 LUGZUJZYTRPEDY-UHFFFAOYSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 108010026552 Proteome Proteins 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 125000004432 carbon atom Chemical group C* 0.000 description 6
- 230000004663 cell proliferation Effects 0.000 description 6
- 230000000593 degrading effect Effects 0.000 description 6
- 238000003119 immunoblot Methods 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 6
- 238000013518 transcription Methods 0.000 description 6
- 230000035897 transcription Effects 0.000 description 6
- HUMARXMRTXDPPK-UHFFFAOYSA-N (2-amino-1,3-thiazol-5-yl) thiocyanate Chemical compound NC1=NC=C(SC#N)S1 HUMARXMRTXDPPK-UHFFFAOYSA-N 0.000 description 5
- AOTQGWFNFTVXNQ-UHFFFAOYSA-N 2-(1-adamantyl)acetic acid Chemical compound C1C(C2)CC3CC2CC1(CC(=O)O)C3 AOTQGWFNFTVXNQ-UHFFFAOYSA-N 0.000 description 5
- WWHZELYGAZRGKC-UHFFFAOYSA-N 2-chloro-n-(3,3-dimethyl-2-oxobutyl)acetamide Chemical compound CC(C)(C)C(=O)CNC(=O)CCl WWHZELYGAZRGKC-UHFFFAOYSA-N 0.000 description 5
- DPBWFNDFMCCGGJ-UHFFFAOYSA-N 4-Piperidine carboxamide Chemical compound NC(=O)C1CCNCC1 DPBWFNDFMCCGGJ-UHFFFAOYSA-N 0.000 description 5
- UNUCZJRZFFSFFA-UHFFFAOYSA-N 5-[(5-tert-butyl-1,3-oxazol-2-yl)methylsulfanyl]-1,3-thiazol-2-amine Chemical compound O1C(C(C)(C)C)=CN=C1CSC1=CN=C(N)S1 UNUCZJRZFFSFFA-UHFFFAOYSA-N 0.000 description 5
- AFVFQIVMOAPDHO-UHFFFAOYSA-M Methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 5
- 102000009572 RNA Polymerase II Human genes 0.000 description 5
- 108010009460 RNA Polymerase II Proteins 0.000 description 5
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- DNUTZBZXLPWRJG-UHFFFAOYSA-M piperidine-1-carboxylate Chemical compound [O-]C(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-M 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 125000003666 tauryl group Chemical group [H]N([H])C([H])([H])C([H])([H])S(*)(=O)=O 0.000 description 5
- ARHCLXWELPFVFQ-UHFFFAOYSA-N 5-bromo-1,3-thiazol-2-amine Chemical compound NC1=NC=C(Br)S1 ARHCLXWELPFVFQ-UHFFFAOYSA-N 0.000 description 4
- 101100383153 Caenorhabditis elegans cdk-9 gene Proteins 0.000 description 4
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 description 4
- 102100036239 Cyclin-dependent kinase 2 Human genes 0.000 description 4
- 102100026810 Cyclin-dependent kinase 7 Human genes 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 101100239628 Danio rerio myca gene Proteins 0.000 description 4
- 101000911952 Homo sapiens Cyclin-dependent kinase 7 Proteins 0.000 description 4
- 101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 description 4
- 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000003698 anagen phase Effects 0.000 description 4
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 238000011894 semi-preparative HPLC Methods 0.000 description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- AVIWDYSJSPOOAR-LSDHHAIUSA-N (1S,3R)-3-acetamido-N-[5-chloro-4-(5,5-dimethyl-4,6-dihydropyrrolo[1,2-b]pyrazol-3-yl)pyridin-2-yl]cyclohexane-1-carboxamide Chemical compound C(C)(=O)N[C@H]1C[C@H](CCC1)C(=O)NC1=NC=C(C(=C1)C1=C2N(N=C1)CC(C2)(C)C)Cl AVIWDYSJSPOOAR-LSDHHAIUSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 102000015367 CRBN Human genes 0.000 description 3
- 230000006820 DNA synthesis Effects 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102100028092 Homeobox protein Nkx-3.1 Human genes 0.000 description 3
- 101000578249 Homo sapiens Homeobox protein Nkx-3.1 Proteins 0.000 description 3
- 101001091365 Homo sapiens Plasma kallikrein Proteins 0.000 description 3
- 101000605534 Homo sapiens Prostate-specific antigen Proteins 0.000 description 3
- 101000941994 Homo sapiens Protein cereblon Proteins 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- 102100034869 Plasma kallikrein Human genes 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 230000018199 S phase Effects 0.000 description 3
- 239000006180 TBST buffer Substances 0.000 description 3
- 102000040945 Transcription factor Human genes 0.000 description 3
- 108091023040 Transcription factor Proteins 0.000 description 3
- 230000001028 anti-proliverative effect Effects 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000012230 colorless oil Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000009520 phase I clinical trial Methods 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 125000006413 ring segment Chemical group 0.000 description 3
- 230000008684 selective degradation Effects 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- JJOIGVWVISBUAZ-UHFFFAOYSA-N 2-(1-adamantyl)propanoic acid Chemical compound C1C(C2)CC3CC2CC1(C(C(O)=O)C)C3 JJOIGVWVISBUAZ-UHFFFAOYSA-N 0.000 description 2
- ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical group NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 description 2
- BLFRQYKZFKYQLO-UHFFFAOYSA-N 4-aminobutan-1-ol Chemical compound NCCCCO BLFRQYKZFKYQLO-UHFFFAOYSA-N 0.000 description 2
- SXIFAEWFOJETOA-UHFFFAOYSA-N 4-hydroxy-butyl Chemical group [CH2]CCCO SXIFAEWFOJETOA-UHFFFAOYSA-N 0.000 description 2
- 206010000830 Acute leukaemia Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108010058546 Cyclin D1 Proteins 0.000 description 2
- 108010068237 Cyclin H Proteins 0.000 description 2
- 102100036883 Cyclin-H Human genes 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
- 230000010190 G1 phase Effects 0.000 description 2
- 102100024165 G1/S-specific cyclin-D1 Human genes 0.000 description 2
- 102100037858 G1/S-specific cyclin-E1 Human genes 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 101000738568 Homo sapiens G1/S-specific cyclin-E1 Proteins 0.000 description 2
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 102000019014 Positive Transcriptional Elongation Factor B Human genes 0.000 description 2
- 108010012271 Positive Transcriptional Elongation Factor B Proteins 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 102000006382 Ribonucleases Human genes 0.000 description 2
- 108010083644 Ribonucleases Proteins 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 230000001594 aberrant effect Effects 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- DZULQZKFBAHSRX-UHFFFAOYSA-N adamantane-1-carbaldehyde Chemical compound C1C(C2)CC3CC2CC1(C=O)C3 DZULQZKFBAHSRX-UHFFFAOYSA-N 0.000 description 2
- JIMXXGFJRDUSRO-UHFFFAOYSA-N adamantane-1-carboxylic acid Chemical compound C1C(C2)CC3CC2CC1(C(=O)O)C3 JIMXXGFJRDUSRO-UHFFFAOYSA-N 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000012054 celltiter-glo Methods 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- HQVFCQRVQFYGRJ-UHFFFAOYSA-N formic acid;hydrate Chemical compound O.OC=O HQVFCQRVQFYGRJ-UHFFFAOYSA-N 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 125000001183 hydrocarbyl group Chemical group 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000005918 in vitro anti-tumor Effects 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000005468 ion implantation Methods 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- CLYOOVNORYNXMD-UHFFFAOYSA-N methyl adamantane-1-carboxylate Chemical compound C1C(C2)CC3CC2CC1(C(=O)OC)C3 CLYOOVNORYNXMD-UHFFFAOYSA-N 0.000 description 2
- MBABOKRGFJTBAE-UHFFFAOYSA-N methyl methanesulfonate Chemical compound COS(C)(=O)=O MBABOKRGFJTBAE-UHFFFAOYSA-N 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000006408 oxalic acid Nutrition 0.000 description 2
- KHPXUQMNIQBQEV-UHFFFAOYSA-N oxaloacetic acid Chemical compound OC(=O)CC(=O)C(O)=O KHPXUQMNIQBQEV-UHFFFAOYSA-N 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 229940124823 proteolysis targeting chimeric molecule Drugs 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 239000012192 staining solution Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000011593 sulfur Chemical group 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 230000001360 synchronised effect Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- MPDDTAJMJCESGV-CTUHWIOQSA-M (3r,5r)-7-[2-(4-fluorophenyl)-5-[methyl-[(1r)-1-phenylethyl]carbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate Chemical compound C1([C@@H](C)N(C)C(=O)C2=NN(C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C2C(C)C)C=2C=CC(F)=CC=2)=CC=CC=C1 MPDDTAJMJCESGV-CTUHWIOQSA-M 0.000 description 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N (e)-2-hydroxybut-2-enedioic acid Chemical compound OC(=O)\C=C(\O)C(O)=O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- MOIZSTYCKHOFQK-UHFFFAOYSA-N 1-(1-adamantyl)propan-1-ol Chemical compound C1C(C2)CC3CC2CC1(C(O)CC)C3 MOIZSTYCKHOFQK-UHFFFAOYSA-N 0.000 description 1
- JWOHBPPVVDQMKB-UHFFFAOYSA-N 1-[(2-methylpropan-2-yl)oxycarbonyl]piperidine-4-carboxylic acid Chemical compound CC(C)(C)OC(=O)N1CCC(C(O)=O)CC1 JWOHBPPVVDQMKB-UHFFFAOYSA-N 0.000 description 1
- MDVGOOIANLZFCP-UHFFFAOYSA-N 1-adamantylmethanol Chemical compound C1C(C2)CC3CC2CC1(CO)C3 MDVGOOIANLZFCP-UHFFFAOYSA-N 0.000 description 1
- JVVRJMXHNUAPHW-UHFFFAOYSA-N 1h-pyrazol-5-amine Chemical class NC=1C=CNN=1 JVVRJMXHNUAPHW-UHFFFAOYSA-N 0.000 description 1
- BLQURGBJSSSGAU-UHFFFAOYSA-N 2-(1-adamantyl)acetaldehyde Chemical compound C1C(C2)CC3CC2CC1(CC=O)C3 BLQURGBJSSSGAU-UHFFFAOYSA-N 0.000 description 1
- ZBIDZPHRNBZTLT-UHFFFAOYSA-N 2-(1-adamantyl)ethanol Chemical compound C1C(C2)CC3CC2CC1(CCO)C3 ZBIDZPHRNBZTLT-UHFFFAOYSA-N 0.000 description 1
- CILPHQCEVYJUDN-VWYCJHECSA-N 2-[(1s,2s,5r)-5-methyl-2-propan-2-ylcyclohexyl]oxyacetic acid Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1OCC(O)=O CILPHQCEVYJUDN-VWYCJHECSA-N 0.000 description 1
- FQIHGPNYNDYFGQ-UHFFFAOYSA-N 2-[2-(2-hydroxyethoxy)ethoxy]acetamide Chemical compound NC(=O)COCCOCCO FQIHGPNYNDYFGQ-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- VHQIDCCICPFCOG-UHFFFAOYSA-N 2-isocyanatoadamantane Chemical compound C1C(C2)CC3CC1C(N=C=O)C2C3 VHQIDCCICPFCOG-UHFFFAOYSA-N 0.000 description 1
- WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- ACWKGTGIJRCOOM-UHFFFAOYSA-N 4-(4-fluoro-2-methoxyphenyl)-n-[3-[(methylsulfonimidoyl)methyl]phenyl]-1,3,5-triazin-2-amine Chemical compound COC1=CC(F)=CC=C1C1=NC=NC(NC=2C=C(CS(C)(=N)=O)C=CC=2)=N1 ACWKGTGIJRCOOM-UHFFFAOYSA-N 0.000 description 1
- HVBSAKJJOYLTQU-UHFFFAOYSA-N 4-aminobenzenesulfonic acid Chemical compound NC1=CC=C(S(O)(=O)=O)C=C1 HVBSAKJJOYLTQU-UHFFFAOYSA-N 0.000 description 1
- YZCUMZWULWOUMD-NDEPHWFRSA-N 5-fluoro-4-(4-fluoro-2-methoxyphenyl)-N-[4-[(methylsulfonimidoyl)methyl]pyridin-2-yl]pyridin-2-amine Chemical compound COc1cc(F)ccc1-c1cc(Nc2cc(C[S@@](C)(=N)=O)ccn2)ncc1F YZCUMZWULWOUMD-NDEPHWFRSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000036764 Adenocarcinoma of the esophagus Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 235000003276 Apios tuberosa Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000010744 Arachis villosulicarpa Nutrition 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 description 1
- 125000005865 C2-C10alkynyl group Chemical group 0.000 description 1
- 101100038180 Caenorhabditis briggsae rpb-1 gene Proteins 0.000 description 1
- 101100038181 Caenorhabditis elegans ama-1 gene Proteins 0.000 description 1
- 101100533230 Caenorhabditis elegans ser-2 gene Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108010060273 Cyclin A2 Proteins 0.000 description 1
- 108010060385 Cyclin B1 Proteins 0.000 description 1
- 102100025191 Cyclin-A2 Human genes 0.000 description 1
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 1
- 108010025454 Cyclin-Dependent Kinase 5 Proteins 0.000 description 1
- 108010025468 Cyclin-Dependent Kinase 6 Proteins 0.000 description 1
- 108010025461 Cyclin-Dependent Kinase 9 Proteins 0.000 description 1
- 102100036876 Cyclin-K Human genes 0.000 description 1
- 102100032857 Cyclin-dependent kinase 1 Human genes 0.000 description 1
- 101710106279 Cyclin-dependent kinase 1 Proteins 0.000 description 1
- 102100033245 Cyclin-dependent kinase 16 Human genes 0.000 description 1
- 102100036252 Cyclin-dependent kinase 4 Human genes 0.000 description 1
- 102100026804 Cyclin-dependent kinase 6 Human genes 0.000 description 1
- 102100026805 Cyclin-dependent-like kinase 5 Human genes 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 101710199605 Endoribonuclease Proteins 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- PLUBXMRUUVWRLT-UHFFFAOYSA-N Ethyl methanesulfonate Chemical compound CCOS(C)(=O)=O PLUBXMRUUVWRLT-UHFFFAOYSA-N 0.000 description 1
- 108010040476 FITC-annexin A5 Proteins 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 230000010337 G2 phase Effects 0.000 description 1
- 102100032340 G2/mitotic-specific cyclin-B1 Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 101000713127 Homo sapiens Cyclin-K Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- BXDZOYLPNAIDOC-UHFFFAOYSA-N N-[5-[(5-tert-butyl-1,3-oxazol-2-yl)methylsulfanyl]-1,3-thiazol-2-yl]-1-[2-[2-[2-[2-[2-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino]ethoxy]ethoxy]ethoxy]ethylamino]-2-oxoethyl]piperidine-4-carboxamide Chemical compound CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCN(CC(=O)NCCOCCOCCOCCNc4cccc5C(=O)N(C6CCC(=O)NC6=O)C(=O)c45)CC3)s2)o1 BXDZOYLPNAIDOC-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 206010030137 Oesophageal adenocarcinoma Diseases 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000269435 Rana <genus> Species 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 101710113029 Serine/threonine-protein kinase Proteins 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical class [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- HIMJIPRMECETLJ-UHFFFAOYSA-N Wogonin Natural products COc1cc(O)c(O)c2C(=O)C=C(Oc12)c3ccccc3 HIMJIPRMECETLJ-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- MTHIUDZOJKVHSV-UHFFFAOYSA-N acetamido methanesulfonate Chemical compound CC(=O)NOS(C)(=O)=O MTHIUDZOJKVHSV-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- XBJFCYDKBDVADW-UHFFFAOYSA-N acetonitrile;formic acid Chemical compound CC#N.OC=O XBJFCYDKBDVADW-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 125000004442 acylamino group Chemical group 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 208000037844 advanced solid tumor Diseases 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000005277 alkyl imino group Chemical group 0.000 description 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 125000000266 alpha-aminoacyl group Chemical group 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 125000001769 aryl amino group Chemical group 0.000 description 1
- 150000005840 aryl radicals Chemical class 0.000 description 1
- 125000005135 aryl sulfinyl group Chemical group 0.000 description 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000001175 calcium sulphate Substances 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 150000007942 carboxylates Chemical group 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 239000008004 cell lysis buffer Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000003021 clonogenic effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 238000003235 crystal violet staining Methods 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000006165 cyclic alkyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 125000004986 diarylamino group Chemical group 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 229940126364 enitociclib Drugs 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 208000028653 esophageal adenocarcinoma Diseases 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 150000002169 ethanolamines Chemical class 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 229940097042 glucuronate Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229940049906 glutamate Drugs 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical compound OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000005553 heteroaryloxy group Chemical group 0.000 description 1
- 125000004366 heterocycloalkenyl group Chemical group 0.000 description 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- URIRDRHUUFRHAS-UHFFFAOYSA-N hexyl methanesulfonate Chemical compound CCCCCCOS(C)(=O)=O URIRDRHUUFRHAS-UHFFFAOYSA-N 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229940045996 isethionic acid Drugs 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229940017219 methyl propionate Drugs 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000000765 microspectrophotometry Methods 0.000 description 1
- 230000035773 mitosis phase Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 1
- 238000001728 nano-filtration Methods 0.000 description 1
- YZMHQCWXYHARLS-UHFFFAOYSA-N naphthalene-1,2-disulfonic acid Chemical compound C1=CC=CC2=C(S(O)(=O)=O)C(S(=O)(=O)O)=CC=C21 YZMHQCWXYHARLS-UHFFFAOYSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 238000003012 network analysis Methods 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 125000005561 phenanthryl group Chemical group 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 1
- 230000000865 phosphorylative effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- UVSMNLNDYGZFPF-UHFFFAOYSA-N pomalidomide Chemical compound O=C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O UVSMNLNDYGZFPF-UHFFFAOYSA-N 0.000 description 1
- 229960000688 pomalidomide Drugs 0.000 description 1
- ZNNZYHKDIALBAK-UHFFFAOYSA-M potassium thiocyanate Chemical compound [K+].[S-]C#N ZNNZYHKDIALBAK-UHFFFAOYSA-M 0.000 description 1
- 229940116357 potassium thiocyanate Drugs 0.000 description 1
- 239000013630 prepared media Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000031877 prophase Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 229940080818 propionamide Drugs 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 238000011865 proteolysis targeting chimera technique Methods 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000001725 pyrenyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000005494 pyridonyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 108010026668 snake venom protein C activator Proteins 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229950000244 sulfanilic acid Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical compound C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000003441 thioacyl group Chemical group 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000011222 transcriptome analysis Methods 0.000 description 1
- QQOWHRYOXYEMTL-UHFFFAOYSA-N triazin-4-amine Chemical class N=C1C=CN=NN1 QQOWHRYOXYEMTL-UHFFFAOYSA-N 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000000169 tricyclic heterocycle group Chemical group 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
- UAEJRRZPRZCUBE-UHFFFAOYSA-N trimethoxyalumane Chemical compound [Al+3].[O-]C.[O-]C.[O-]C UAEJRRZPRZCUBE-UHFFFAOYSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 238000001195 ultra high performance liquid chromatography Methods 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- XLTFNNCXVBYBSX-UHFFFAOYSA-N wogonin Chemical compound COC1=C(O)C=C(O)C(C(C=2)=O)=C1OC=2C1=CC=CC=C1 XLTFNNCXVBYBSX-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
The invention relates to an oxazole compound and a preparation method and application thereof, and in particular discloses an oxazole compound represented by a general formula I, and pharmaceutically acceptable salts, enantiomers, diastereomers, racemates, atropisomers, polymorphs, solvates or isotopically labeled compounds thereof. The compound shown in the formula (I) has high-efficiency and selective CDK9-cyclin T1 complex degradation, and can be used for preparing medicines for preventing and/or treating diseases or symptoms mediated by CDK9-cyclin T1 complex, especially tumors.
Description
Technical Field
The invention relates to the field of biological medicine, in particular to a compound for degrading CDK9-cyclin T1 complex, a preparation method, a pharmaceutical composition and application thereof.
Background
Cyclin-dependent kinases (CDKs) are important regulatory proteins in the life cycle activities of mammalian cells, belonging to the conserved serine/threonine protein kinase family. CDKs consist of a dimeric complex of a cell cycle catalytic subunit and a regulatory subunit, which bind to cyclin (cyclin) and bind to a cell cycle (including the prophase of DNA synthesis (G) 1 Stage), DNA synthesis stage (S stage), DNA synthesis late stage (G) 2 Phase), mitosis phase (M phase), and G in a dormant state of cells 0 Phase), transcription of cells, DNA damage and repair, stem cells, metabolism, epigenetic and angiogenic processes. It has now been found that the human genome encodes 21 CDKs and 29 cyclin proteins, which are divided into two classes according to their primary functions: one is a subfamily that regulates cell cycle, including regulation of G 1 CDKs (CDK 2-cyclin E, CDK4-cyclin D, CDK6-cyclin D, etc.) and modulation of S phase/G 2 CDKs (CDK 1-cyclin A, CDK1-cyclin B, CDK2-cyclin A, etc.) of phase/M; one class is CDK7-cyclin H, CDK8-cyclin C, CDK9-cyclin T, CDK11-cyclin L, etc. that are involved in cell transcriptional regulation. The CDKs subfamilies which are divided according to functions act on each regulation site in a cooperativity and periodicity mode in the whole cell growth and proliferation process, so that the normal operation of the whole cell life cycle is ensured. Since tumors and various proliferative diseases are caused by abnormal changes in the cell cycle, CDKs are important targets for the treatment of these diseases.
Cyclin-dependent kinase 9 (CDK 9) forms a complex with cyclin T or cyclin K as a CDKs family member, forward transcriptionally-extending factor b (P-TEFb), which regulates cellular transcription by phosphorylating the carboxy-terminal domain (CTD) of the largest subunit (RPB 1) of RNA polymerase II (RNAPII) to facilitate transcriptional extension. Given that P-TEFb is a universal transcription factor for the efficient expression of most genes, CDK9 is widely found in the transcription process of normal cells and thus does not appear to be an ideal target for the treatment of any disease. However, a great deal of research shows that CDK9 is closely related to pathogenesis of tumors (leukemia, breast cancer and liver cancer), heart diseases and AIDS, and is a key target of the related drugs for the diseases. Through studies of the CDK9 structure, it was found that it has a folding region of the protein kinase consisting of C-and N-terminal kinase domains and a short C-terminal extension, the cleft between the N-and C-terminal kinase leaves being an ATP binding site and being highly conserved, many fragments in the ATP binding pocket, such as the α -helix, hinge and G-loop regions, have better flexibility than other CDKs family members, creating ideal conditions for the development of specific CDK9 inhibitors.
In recent years, this field has reported a variety of highly selective CDK9 inhibitors, some of which have entered the clinical trial phase. Bayer in 2017 developed the first highly specific CDK9 inhibitor Atuveciclib (BAY-1143572), which is an aminotriazine derivative, and is currently in phase I clinical trials for the treatment of advanced acute leukemia. BAY-1143572 has been reported to have synergistic anti-esophageal adenocarcinoma effects with 5-fluorouracil and also significantly reduce invasion of ATL tumors in the liver and bone marrow of mice. After this, bayer company has further developed a second highly selective CDK9 inhibitor, BAY-1251152 with an aminopyridine structure, which is in phase i clinical trials for the treatment of acute leukemia and the treatment of advanced solid tumors with single agents. In addition, the novel high-efficiency aminopyridine structure CDK9 inhibitor AZD-4573 is also developed by the aspartame, and the drug is in the phase I clinical trial stage of the malignant tumor of the blood system. Research shows that AZD-4573 has good activity in xenograft tumor models of multiple blood tumors, and the combination of the AZD-4573 and a tyrosine kinase (BTK) inhibitor, namely Acalabarutinib, improves the anti-tumor activity.
In addition to the large number of reported specific inhibitors of CDK9, more work has focused on the study of specific degradants of CDK 9. The sandep Rana topic group in 2017 reported the first selective degradants of CDK9 based on proteolytically targeted chimeras (Proteolysis targeting chimera, PROTAC). The structure of the molecule is a connector of aminopyrazole derivative and CRBN ligand thalid, and western blots experiments show that the concentration of the degradation agent can reduce CDK9 protein expression by 56% and 65% when 10 mu M and 20 mu M. In 2018, the Nathanael S.Gray team developed a CDK9 selective degradation agent, THAL-SNS-032, based on the inhibitor SNS-032 of CDK9 and the CRBN ligand, thaldimide, which induced rapid degradation of 99% CDK9 at 50nM and did not affect the expression of proteins at other SNS-032 targets, and furthermore had a more durable pharmacokinetic effect compared to other inhibitors. The Zhiyu Li team 2018 also reported a selective degradation agent for CDK9 based on the natural product wogonin and CRBN ligand pomalidomide, which compound showed good cell proliferation inhibitory activity (ic50=17±1.9 μm) and low activity against CDK 9-low expressing cell lines with good selectivity profile.
Although many specific inhibitors targeting CDK9 and selective degradants for proac-based CDK9 are reported today, the currently reported CDK9 degradants are designed based on CDK9 and mainly cause degradation of monomeric CDK9 with little impact on cyclin T1. Considering that cyclin T1 performs many non-catalytic functions, a small molecule degradation agent that degrades CDK9-cyclin T1 complex is an urgent object to be developed.
Disclosure of Invention
Based on the above problems in the prior art, it is an object of the present invention to provide a pharmaceutical composition comprising a 5- (tert-butyl) -2- ((thiazol-5-ylthio) methyl) oxazole compound or a pharmaceutically acceptable salt, enantiomer, diastereomer, racemate, atropisomer, polymorph, solvate or isotopically labeled compound thereof.
It is another object of the present invention to provide a process for the preparation of the above compounds.
It is a further object of the present invention to provide a pharmaceutical composition comprising a therapeutically effective amount of one or more of the above compounds, or pharmaceutically acceptable salts, enantiomers, diastereomers, racemates, atropisomers, polymorphs, solvates or isotopically-labeled compounds thereof.
It is a further object of the present invention to provide the use of a compound as defined above, or a pharmaceutically acceptable salt, enantiomer, diastereomer, racemate, atropisomer, polymorph, solvate or isotopically-labelled compound thereof, in the manufacture of a medicament for the treatment of a disease or condition mediated by CDK9 and/or cyclin T1 dysfunction.
It is a further object of the present invention to provide a method of treating a disease or condition mediated by CDK9 and/or cyclin T1 dysfunction, comprising administering to a subject a therapeutically effective amount of one or more of the above compounds, or pharmaceutically acceptable salts, enantiomers, diastereomers, racemates, atropisomers, polymorphs, solvates or isotopically labeled compounds thereof.
In a first aspect of the present invention, there is provided an oxazole compound of the general formula I, a pharmaceutically acceptable salt, enantiomer, diastereomer, racemate, atropisomer, polymorph, solvate, or isotopically labeled compound thereof:
wherein A is selected from-C (=O) (CH 2 ) x -、-C(=O)(CH 2 ) x NHC(=O)-、-(CH 2 ) x NHC(=O)(CH 2 ) y -、-(CH 2 ) x -、-(CH 2 CH 2 O) x (CH 2 ) y NHC(=O)CH 2 -、-(CH 2 ) x -B-C(=O)(CH 2 ) y -、-S(=O) 2 (CH 2 ) x NHC(=O)(CH 2 ) y -、-S(=O) 2 (CH 2 ) x NHC(=O)NH-;
x is independently selected from 0, 1, 2, 3, 4, 5, 6;
y is independently selected from 0, 1, 2;
b is a 4-8 membered heterocyclic ring containing 1, 2 or 3 heteroatoms selected from N, O, S; preferably a 4-6 membered heterocyclic ring, the heteroatom being N; more preferably the heterocycle is azetidine, azacyclopentane, azacyclohexane; more preferably B is Wherein z is independently selected from 1, 2, 3; particularly preferred is +.>
R is selected from C 1 -C 10 Alkyl, C 3 -C 10 Cycloalkyl, C 3 -C 10 Cycloalkyl oxy, C 6 -C 12 Aryl, 5-7 membered heteroaryl, the foregoing C 1 -C 10 Alkyl, C 3 -C 10 Cycloalkyl, C 3 -C 10 Cycloalkyl oxy, C 6 -C 12 Aryl, 5-7 membered heteroaryl groups may be substituted with one or more of the following groups: c (C) 1 -C 6 Alkyl, deuterium, halogen, cyano, nitro, amino, hydroxy, halogen substituted C 1 -C 6 Alkyl, hydroxy substituted C 1 -C 6 Alkyl, C 1 -C 6 Alkyloxy, halogen substituted C 1 -C 6 Alkyloxy, phenyl, -NH-Boc-, - (CH) 2 ) z -N=C(NH-Boc) 2 The heteroaryl contains 1, 2 or 3 heteroatoms selected from N, O, S, and z is 0, 1, 2 or 3; r is preferably selected from C 1 -C 6 Alkyl, C 3 -C 10 Cycloalkyl, C 3 -C 8 Cycloalkyl oxy, C 1 -C 6 Alkyl, C 3 -C 10 Cycloalkyl, C 3 -C 8 The cycloalkyloxy group may be substituted with one or more of the following groups: c (C) 1 -C 6 Alkyl, deuterium, halogen, cyano, nitro, amino, hydroxy, halogen substituted C 1 -C 6 Alkyl, hydroxy substituted C 1 -C 6 Alkyl, C 1 -C 6 Alkyloxy, halogen substituted C 1 -C 6 Alkyloxy, phenyl, -NH-Boc-, - (CH) 2 ) z -N=C(NH-Boc) 2 Z is 0, 1, 2 or 3; r is more preferably selected from C 1 -C 4 Alkyl, C 3 -C 10 Cycloalkyl, C 3 -C 6 Cycloalkyl oxy, C 1 -C 4 Alkyl, C 3 -C 10 Cycloalkyl, C 3 -C 6 The cycloalkyloxy group may be substituted with one or more of the following groups: c (C) 1 -C 4 Alkyl, deuterium, halogen, cyano, nitro, amino, hydroxy, halogen substituted C 1 -C 4 Alkyl, hydroxy substituted C 1 -C 4 Alkyl, C 1 -C 4 Alkyloxy, halogen substituted C 1 -C 4 Alkyloxy, phenyl, -NH-Boc-, - (CH) 2 ) 3 -N=C(NH-Boc) 2 The method comprises the steps of carrying out a first treatment on the surface of the R is more preferably selected from the group consisting of methyl, ethyl, n-propyl, cyclopentyl, cyclohexyl, cycloheptyl, adamantyl, cyclopentyloxy, cyclohexyloxy, cycloheptyloxy, the foregoing methyl, ethyl, propyl, cyclopentyl, cyclohexyl, cycloheptyl, adamantyl, cyclopentyloxy, cyclohexyloxy, cycloheptyloxy being substituted with one or more of the following groups: methyl, ethyl, n-propyl, isopropyl, deuterium, halogen, cyano, nitro, amino, hydroxy, phenyl, -NH-Boc-, - (CH) 2 ) 3 -N=C(NH-Boc) 2 The method comprises the steps of carrying out a first treatment on the surface of the More preferably, R is selected from adamantyl, cyclohexyloxy, triphenylmethyl, 2-triphenylethyl, unsubstituted or substituted with one or two members selected from the group consisting of methyl, isopropyl,further preferred, R is selected from adamantyl,/->Triphenylmethyl, 2-triphenylethyl, -, and->
In some preferred embodiments, according to the invention, in the definition of substituents, a is selected from-C (=o) (CH 2 ) x -、-C(=O)(CH 2 ) x NHC(=O)-、-(CH 2 ) x NHC(=O)(CH 2 ) y -、-(CH 2 ) x -、-(CH 2 CH 2 O) x (CH 2 ) y NHC(=O)CH 2 -、-(CH 2 ) x -B-C(=O)(CH 2 ) y -、-S(=O) 2 (CH 2 ) x NHC(=O)(CH 2 ) y -、-S(=O) 2 (CH 2 ) x NHC(=O)NH-;
x is independently selected from 0, 1, 2, 3, 4, 5, 6;
y is independently selected from 0, 1, 2;
b is 4-8 membered nitrogen heterocycle;
r is selected from C 1 -C 10 Alkyl, C 3 -C 10 Cycloalkyl, C 3 -C 10 Cycloalkyl oxy, C 1 -C 10 Alkyl, C 3 -C 10 Cycloalkyl, C 3 -C 10 The cycloalkyloxy group may be substituted with one or more of the following groups: c (C) 1 -C 6 Alkyl, deuterium, halogen, cyano, nitro, amino, hydroxy, halogen substituted C 1 -C 6 Alkyl, hydroxy substituted C 1 -C 6 Alkyl, C 1 -C 6 Alkyloxy, halogen substituted C 1 -C 6 Alkyloxy, phenyl, -NH-Boc, - (CH) 2 ) 3 -N=C(NH-Boc) 2 。
In some preferred embodiments, a is selected from-C (=o) (CH 2 ) x -、-C(=O)(CH 2 ) x NHC(=O)-、-(CH 2 ) x NHC(=O)(CH 2 ) y -、-(CH 2 ) x -、-(CH 2 CH 2 O) x (CH 2 ) y NHC(=O)CH 2 -、-(CH 2 ) x -B-C(=O)(CH 2 ) y -、-S(=O) 2 (CH 2 ) x NHC(=O)(CH 2 ) y -、-S(=O) 2 (CH 2 ) x NHC(=O)NH-;
x is independently selected from 0, 1, 2, 3, 4, 6;
y is independently selected from 0, 1, 2;
b is 4-8 membered nitrogen heterocycle;
r is selected from C 1 -C 10 Alkyl, C 3 -C 10 Cycloalkyl, C 3 -C 8 Cycloalkyl oxy, C 1 -C 10 Alkyl, C 3 -C 10 Cycloalkyl, C 3 -C 8 The cycloalkyloxy group may be substituted with one or more (e.g., 1, 2, or 3) of the following groups: c (C) 1 -C 6 Alkyl, phenyl, -NH-Boc, - (CH) 2 ) 3 -N=C(NH-Boc) 2 The method comprises the steps of carrying out a first treatment on the surface of the Preferably selected from C 1 -C 4 Alkyl, C 3 -C 10 Cycloalkyl, C 3 -C 8 Cycloalkyl oxy, C 1 -C 4 Alkyl, C 3 -C 10 Cycloalkyl, C 3 -C 8 The cycloalkyloxy group may be substituted with one or more of the following groups: c (C) 1 -C 4 Alkyl, phenyl, -NH-Boc- (CH) 2 ) 3 -N=C(NH-Boc) 2 。
In some preferred embodiments, a is selected from-C (=o) (CH 2 ) x -、-C(=O)(CH 2 ) x NHC(=O)-、-(CH 2 ) x NHC(=O)(CH 2 ) y -、-(CH 2 ) x -、-(CH 2 CH 2 O) x (CH 2 ) y NHC(=O)CH 2 -、-(CH 2 ) x -B-C(=O)(CH 2 ) y -、-S(=O) 2 (CH 2 ) x NHC(=O)(CH 2 ) y -、-S(=O) 2 (CH 2 ) x NHC(=O)NH-;
x is independently selected from 0, 1, 2, 3, 4, 5, 6;
y is independently selected from 0, 1, 2;
b is 6-membered nitrogen heterocyclyl;
R is selected from methyl, ethyl, n-propyl, cyclopentyl, cyclohexyl, cycloheptyl, adamantyl, cyclopentyloxy, cyclohexyloxy, cycloheptyloxy, the foregoing methyl, ethyl, n-propyl, cyclopentyl, cyclohexyl, cycloheptyl, adamantyl, cyclopentyloxy, cyclohexyloxy, cycloheptyloxy may be substituted with one or more of the following groups: methyl, ethyl, n-propyl, isopropyl, deuterium, halogen, cyano, nitro, amino, hydroxy, phenyl, -NH-Boc-, - (CH) 2 ) 3 -N=C(NH-Boc) 2 。
In one embodiment, a is preferably selected from-C (=o) CH 2 -、-C(=O)(CH 2 ) 2 -、-C(=O)CH 2 NHC(=O)-、-(CH 2 ) 2 NHC(=O)-、-(CH 2 ) 4 NHC(=O)CH 2 -、-(CH 2 ) 6 NHC(=O)-CH 2 -、-(CH 2 ) 2 NHC(=O)CH 2 -、-CH 2 -、-(CH 2 ) 2 -、-(CH 2 ) 3 -、-CH 2 CH 2 O-(CH 2 ) 2 NHC(=O)CH 2 -、-(CH 2 CH 2 O) 2 (CH 2 ) 2 NHC(=O)CH 2 -、-CH 2 -B-C(=O)CH 2 -、-S(=O) 2 (CH 2 ) 2 NHC(=O)CH 2 -、-S(=O) 2 (CH 2 ) 2 NHC(=O)NH-、-S(=O) 2 (CH 2 ) 2 NHC (=o) -; the other substituents are as defined above.
More preferably, the process is carried out,
a is preferably selected from-C (=O) CH 2 -、-C(=O)(CH 2 ) 2 -、-C(=O)CH 2 NHC(=O)-、-(CH 2 ) 2 NHC(=O)-、-(CH 2 ) 4 NHC(=O)CH 2 -、-(CH 2 ) 6 NHC(=O)CH 2 -、-(CH 2 ) 2 NHC(=O)CH 2 -、-CH 2 -、-(CH 2 ) 2 -、-(CH 2 ) 3 -、-CH 2 CH 2 O-(CH 2 ) 2 NHC(=O)CH 2 -、-(CH 2 CH 2 O) 2 (CH 2 ) 2 NHC(=O)CH 2 -、-CH 2 -B-C(=O)CH 2 -、-S(=O) 2 (CH 2 ) 2 NHC(=O)CH 2 -、-S(=O) 2 (CH 2 ) 2 NHC(=O)NH-、-S(=O) 2 (CH 2 ) 2 NHC(=O)-;
B isWherein the method comprises the steps ofz is independently selected from 1, 2, 3; particularly preferred is +.>
R is selected from adamantyl, cyclohexyloxy, triphenylmethyl, 2-triphenylethyl, unsubstituted or substituted by one or two selected from methyl, isopropyl,further preferred, R is selected from adamantyl,/->Triphenylmethyl, 2-triphenylethyl, -, and->
In some preferred embodiments, the compound of formula (I) is specifically selected from the following structures:
wherein x, y, R are as defined previously and n is 1, 2, 3 or 4.
According to the invention, particularly preferably, the compounds of formula (I) above are:
In a second aspect of the present invention, there is provided a process for the preparation of a compound of formula (I) as defined above. All final compounds of the invention are prepared by the methods described in or analogous to these schemes, which are well known to those of ordinary skill in the art of organic chemistry, and all variables employed in these schemes are defined below.
The method is selected from one of the following methods:
the synthesis method comprises the following steps:
wherein R is as previously defined;
step 1-1: the compounds 1A and 1B are activated by HATU and DIPEA in dimethylformamide solution at room temperature to generate a compound 1C through amidation reaction;
or alternatively, the first and second heat exchangers may be,
wherein R is as previously defined;
step 1-2: reacting the compound 1D with trimethyl phosphorylacetate in tetrahydrofuran solution at 0-5 ℃ in the presence of sodium hydride to generate a compound 1E;
step 1-3: dissolving the compound 1E in methanol, adding sodium hydroxide aqueous solution, and hydrolyzing at 70 ℃ to generate a compound 1F;
step 1-4: the compound 1F is hydrogenated in methanol solution by Pd/C catalyst to obtain compound 1G;
step 1-5: the compound 1G and the compound 1A are activated by HATU and DIPEA in dimethylformamide solution at room temperature to generate a compound 1H through amidation reaction;
The synthesis method II comprises the following steps:
wherein R is as previously defined;
step 2-1: the compound 2A, glycine methyl ester hydrochloride and triethylamine are activated in dimethylformamide solution at room temperature, and then are reacted to generate a compound 2B through EDCI and HOBt;
step 2-2: dissolving the compound 2B in methanol, adding sodium hydroxide aqueous solution, and hydrolyzing at 70 ℃ to generate a compound 2C;
step 2-3: the compound 2C and the compound 1A are activated by HATU and DIPEA in dimethylformamide solution at room temperature to generate a compound 2D through amidation reaction;
and a synthesis method III:
wherein R is as previously defined;
step 3-1: the compound 3A and 2, 2-diethoxyethyl-1-amine are activated by HATU and DIPEA in dimethylformamide solution at room temperature to generate a compound 3B through amidation reaction;
step 3-2: dissolving the compound 3B in acetonitrile, adding a 1N hydrochloric acid solution, and reacting at room temperature to obtain a compound 3C;
step 3-3: reacting the compound 3C with the compound 1A and triethylamine in a dichloromethane solution at room temperature in the presence of sodium triacetoxyborohydride to generate a compound 3D;
and a synthesis method:
wherein R is as previously defined; n is taken from 0,1,2,3,4,5;
Step 4-1: reducing the compound 4A into a compound 4B by lithium aluminum hydride in tetrahydrofuran solution at 0 ℃;
step 4-2: dissolving oxalyl chloride in dichloromethane solution, cooling to-78deg.C, adding DMSO, reacting for a period of time, adding compound 4B, reacting, adding triethylamine, heating to room temperature, and reacting to obtain compound 4C;
step 4-3: reacting compound 4C with compound 1A and triethylamine in a dichloromethane solution in the presence of sodium triacetoxyborohydride at room temperature to produce 4D;
or alternatively, the first and second heat exchangers may be,
wherein R is as previously defined; n is taken from 0,1,2,3,4,5;
step 4-4: adding concentrated sulfuric acid into a methanol solution of the compound 4A, and reacting at 80 ℃ to obtain a compound 4E;
step 4-5: compound 4E was reduced to compound 4B by lithium aluminum hydride in tetrahydrofuran solution at 0 ℃;
step 4-6: the compound 4B reacts with pyridine chlorochromate in dichloromethane solution at room temperature to obtain a compound 4C;
step 4-7: reacting compound 4C with compound 1A and triethylamine in a dichloromethane solution in the presence of sodium triacetoxyborohydride at room temperature to produce 4D;
the synthesis method is as follows:
/>
wherein X is- (CH) 2 ) x -,-(CH 2 CH 2 O) x (CH 2 ) y -x, y, R are as previously defined;
Step 5-1: the compound 5A and the compound 5B are activated by HATU and DIPEA in dimethylformamide solution at room temperature to generate a compound 5C through amidation reaction;
step 5-2: adding triethylamine into a dichloromethane solution of the compound 5C, cooling to 0 ℃, dropwise adding a dichloromethane solution of methanesulfonic anhydride, and reacting at room temperature to generate a compound 5D;
step 5-3: reacting the compound 5D with the compound 1A in a dimethylformamide solution at 80 ℃ in the presence of triethylamine to generate a compound 5E;
or alternatively, the first and second heat exchangers may be,
r is as defined above, n is selected from 0,1,2,3;
step 5-4: the compound 5A and the compound 5F are activated by HATU and DIPEA in dimethylformamide solution at room temperature to generate a compound 5G through amidation reaction;
step 5-5: adding triethylamine into a dichloromethane solution of the compound 5G, cooling to 0 ℃, dropwise adding a dichloromethane solution of methanesulfonic anhydride, and reacting at room temperature to generate a compound 5H;
step 5-6: reacting the compound 5H with the compound 1A in dimethylformamide solution at 80 ℃ in the presence of triethylamine to generate a compound 5I;
the synthesis method is six:
wherein R is as previously defined;
step 6-1: the compound 1A and chloroethane-1-sulfonyl chloride react in methylene dichloride solution at the temperature of minus 40 ℃ in the presence of triethylamine to generate a compound 6A;
Step 6-2: compound 6A is reacted in acetonitrile solution at room temperature in the presence of cesium carbonate and ammonium hydroxide to produce compound 6B;
step 6-3: compound 6B and compound 6C are activated by HATU and DIPEA in dimethylformamide solution at room temperature to generate compound 6D through amidation reaction; or the compound 6B and the compound 6C are subjected to amidation reaction in acetonitrile solution in the presence of N-methylimidazole and tetramethyl chlorourea hexafluorophosphate to generate a compound 6D;
step 6-4: compound 6B and compound 6E were reacted in dichloromethane solution at room temperature to yield compound 6F.
In a third aspect of the present application, there is provided a pharmaceutical composition comprising a compound of the first aspect, one or more of its pharmaceutically acceptable salts, enantiomers, diastereomers, atropisomers, racemates, polymorphs, solvates, or isotopically-labeled compounds, and a pharmaceutically acceptable carrier, diluent or excipient.
In another preferred embodiment, the pharmaceutical composition further comprises at least one additional therapeutic agent selected from the group consisting of an anticancer agent, an immunomodulating agent, an anti-inflammatory agent, an anti-alzheimer agent and combinations thereof.
In a fourth aspect of the invention there is provided the use of a compound according to the first aspect, a pharmaceutically acceptable salt, enantiomer, diastereomer, atropisomer, polymorph, solvate, isotopically-labelled compound or racemate thereof, or a pharmaceutical composition according to the second aspect, for the manufacture of a medicament for the prophylaxis and/or treatment of a disease or condition mediated by the CDK9-cyclin T1 complex.
In another preferred embodiment, the disease or disorder mediated by the CDK9-cyclin T1 complex is selected from the group consisting of: breast cancer, osteosarcoma, endometrial tumor, leukemia, lung cancer, prostate cancer, melanoma, ovarian cancer, multiple myeloma, mesothelioma, gastric cancer, malignant rhabdoid tumor, hepatocellular carcinoma, biliary tract cancer, bladder cancer, brain tumor, neuroblastoma, schwannoma, glioma, glioblastoma, astrocytoma, endometrial cancer, esophageal cancer, head and neck cancer, pancreatic cancer, renal cell carcinoma.
In a fifth aspect of the invention there is provided a method of treating a disease or condition mediated by the CDK9-cyclin T1 complex, particularly a tumour, comprising administering to a subject a therapeutically effective amount of one or more compounds described above or pharmaceutically acceptable salts, enantiomers, diastereomers, racemates, atropisomers, polymorphs, solvates or isotopically labelled compounds thereof. In some embodiments, the method further comprises administering to a subject in need thereof an effective dose of an additional therapeutic agent.
The beneficial effects are that:
the invention synthesizes a series of high-efficiency and selective CDK9-cyclin T1 complex small molecule degradation agent derivatives. The previously reported CDK9 small molecule degrading agent mainly aims at CDK9 monomeric protein, and the compound disclosed by the invention can selectively degrade CDK9 and cyclin T1 simultaneously to degrade CDK9-cyclin T1 complex.
At the cellular level, the compound of the invention has proved to obviously inhibit the proliferation of prostate cancer cells, block the cell cycle, induce apoptosis and have stronger effect than the inhibitor SNS032. At the protein level, compound LL-K9-015 significantly inhibited the phosphorylation level of RNA pol II, significantly down-regulated the protein levels of MCL1, cMyc, AR, ARv7, KLK3, NKX3-1, and the inhibition was more complete than SNS032. At the transcriptome level MYC and AR mediated carcinomatous aberrant transcription is inhibited. This is the first case study using small molecule degradants to explore the therapeutic potential against the CDK9-cyclin T1 complex.
The CDK9-cyclin T1 complex small molecule degradation agent, such as LL-K9-015, is a powerful and selective CDK9-cyclin T1 complex small molecule degradation agent, and is a valuable chemical probe for non-catalytic related functional research of CDK9-cyclin T1 complexes.
It is understood that within the scope of the present invention, the above-described technical features of the present invention and technical features specifically described below (e.g., in the examples) may be combined with each other to constitute new or preferred technical solutions. Each feature disclosed in the description may be replaced by alternative features serving the same, equivalent or similar purpose. And are limited to a space, and are not described in detail herein.
Drawings
FIG. 1 shows the measurement results of the activity of the compound of the invention in degrading CDK9-cyclin T1 complex.
FIG. 2 shows degradation potency DC of LL-K9-015 50 Wherein A is the result of immunoblot analysis of LL-K9-015 degradation of CDK9-cyclin T1 complex; b is a degradation efficacy curve of LL-K9-015 fitted according to three independent replicates.
FIG. 3 is a graph showing the results of proteomic assays of the kinetics of degradation of the CDK9-cyclin T1 complex by LL-K9-015, wherein A is the relative protein level change of CDK9 and cyclin T1 over time in 22RV1 cells treated with LL-K9-015; b is the relative protein levels of CDK9 and cyclin T1 in 22RV1 cells treated with SNS032 over time.
FIG. 4 shows the results of immunoblotting for determining the kinetics of degradation of LL-K9-015 to CDK9-cyclin T1 complex.
FIG. 5 shows the results of degradation selectivity, wherein A is the CDK protein content of 22RV1 cells treated with LL-K9-015 for 24 hours; b is the amount of cyclin proteins binding CDK2, CDK7 and CDK9 after treatment of 22RV1 cells for 24 hours with LL-K9-015; c is the proteome change caused by LL-K9-015 group relative to control group (DMSO); d is the proteome change caused by SNS032 relative to the control (DMSO).
FIG. 6 shows the results of in vitro antitumor activity, wherein A is the effect of SNS032 and LL-K9-015 treatment of 22RV1 cells on cell viability for 5 days; b is the effect of SNS032 and LL-K9-015 on clone formation.
FIG. 7 is a graph showing the cell cycle and apoptosis results, wherein A is the distribution of cell cycles 24 hours after treatment of cells with LL-K9-015 and SNS032, and bar graphs represent mean.+ -. Standard deviation of two independent experiments; b is the result of detecting apoptosis after 24 hours of cell action of LL-K9-015 and SNS032, each point represents the result of an independent experiment, and the bar graph represents mean.+ -. Standard deviation, n=3.
FIG. 8 is an immunoblot analysis of CDK 9-associated pathways and proteins of target proteins, wherein A is the result of the immunoblot analysis of CTD phosphorylation and CDK9 target protein levels; b is the result of immunoblot analysis of AR and AR downstream signaling pathways.
FIG. 9 is a thermal graph of the effect of degradants on transcriptomes, wherein A is the heat map of each set of differential genes; b is the transcription factor network analysis of the genes specifically affected by LL-K9-015, and the name of the hinge transcription factor is shown in the figure; c is a heat map of a representative MYC target gene; d is a heat map of a representative AR target gene.
Detailed Description
The invention will be further illustrated with reference to specific examples. It is to be understood that these examples are illustrative of the present invention and are not intended to limit the scope of the present invention. The experimental procedures, which do not address the specific conditions in the examples below, are generally carried out under conventional conditions (e.g.those described in Sambrook et al, molecular cloning: A laboratory Manual (New York: cold Spring Harbor Laboratory Press, 1989)) or under conditions recommended by the manufacturer. Percentages and parts are weight percentages and parts unless otherwise indicated.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. In addition, any methods and materials similar or equivalent to those described herein can be used in the methods of the present invention. The preferred methods and materials described herein are presented for illustrative purposes only.
Through extensive and intensive studies, the inventor of the application synthesizes a series of high-efficiency and selective small molecule degradation agent derivatives of CDK9-cyclin T1 complex with a new oxazole skeleton structure. At the cellular level, the compounds can obviously inhibit the proliferation of prostate cancer cells, block the cell cycle, induce apoptosis, and down regulate the level of regulated proteins of CDK9-cyclin T1 complex, including cMyc, MCL-1, AR and the like. At the transcriptome level MYC and AR mediated carcinomatous aberrant transcription is inhibited.
Terminology
In the present invention, unless otherwise indicated, terms used have the ordinary meanings known to those skilled in the art.
In the present invention, the term "C 1 -C 10 "means having 1, 2, 3, 4, 5,6. 7, 8, 9 or 10 carbon atoms, "C 3 -C 10 "means having 3, 4, 5, 6, 7, 8, 9, 10 carbon atoms, the term" C 1 -C 4 ”、“C 1 -C 6 ”、“C 3 -C 8 ”、“C 6 -C 12 "has a similar meaning.
In the present invention, the term "4-8 membered" means having 4-8 ring atoms, the term "5-7 membered" means having 5-7 ring atoms, and so on.
In the present invention, the term "alkyl" means a saturated straight or branched chain linear hydrocarbon moiety, e.g., the term "C 1 -C 10 Alkyl "refers to a straight or branched alkyl group having 1 to 10 carbon atoms and includes, without limitation, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl and the like; ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl and tert-butyl are preferred; the term "C 1 -C 6 Alkyl ", C 1 -C 4 Alkyl has similar meaning.
In the present invention, the term "cycloalkyl" means a saturated cyclic hydrocarbyl moiety, including monocyclic, bicyclic, and tricyclic, e.g., the term "C 3 -C 10 Cycloalkyl "refers to a cyclic alkyl group having 3 to 10 carbon atoms in the ring and includes, without limitation, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclodecyl, adamantyl (exemplary tricyclic cycloalkyl groups), and the like.
In the present invention, the term "C 3 -C 10 Cycloalkyloxy "refers to a cyclic alkyl-oxy group having 3 to 10 carbon atoms in the ring, including, without limitation, cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy, cycloheptyloxy, cyclooctyloxy, cyclononanyloxy, cyclodecyloxy. The term "C 3 -C 8 Cycloalkyloxy "has similar meaning.
In the present invention, the term "aryl" means a hydrocarbyl moiety comprising one or more aromatic rings. For example, the term "C 6 -C 12 Aryl radicals "Refers to an aromatic cyclic group having 6 to 12 carbon atoms, such as phenyl, naphthyl, etc., which does not contain a heteroatom in the ring. Examples of aryl groups include, but are not limited to, phenyl (Ph), naphthyl, pyrenyl, anthryl, and phenanthryl.
The term "heterocycle" refers to a saturated or partially unsaturated, non-aromatic heterocycle of three to fifteen members, preferably three to ten members, comprising one to four heteroatoms selected from oxygen, nitrogen and sulfur: mono-, bi-or tricyclic heterocycles containing one to three nitrogen atoms and/or one oxygen or sulfur atom or one or two oxygen and/or sulfur atoms in addition to the carbocycle members; if the ring contains more than one oxygen atom, they are not directly adjacent; such as, but not limited to, oxiranyl, oxetanyl, aziridinyl, azetidinyl, and the like.
The term "heteroaryl" refers to a monocyclic or bicyclic aromatic ring radical containing at least one heteroatom selected from nitrogen, oxygen or sulfur as ring member; "5-7 membered heteroaryl" refers to heteroaryl groups containing 5 to 7 ring atoms. Examples of heteroaryl groups include, but are not limited to, the following groups: pyrrolyl, imidazolyl, pyrazolyl, 1,2, 3-triazolyl, pyridinyl, pyridonyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, thiadiazolyl, quinolinyl, and the like.
In the present invention, the term Boc means t-butoxycarbonyl (t-Butyloxy carbonyl).
Unless otherwise indicated, alkyl, cycloalkyl, cycloalkyloxy, aryl, and heteroaryl groups described herein are substituted and unsubstituted groups. Possible substituents on alkyl, cycloalkyl, cycloalkyloxy, aryl and heteroaryl groups include, but are not limited to: hydroxy, amino, nitro, nitrile, halogen, C1-C6 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C20 cycloalkyl, C3-C20 cycloalkenyl, C1-C20 heterocycloalkyl, C1-C20 heterocycloalkenyl, C1-C6 alkoxy, aryl, heteroaryl, heteroaryloxy, C1-C10 alkylamino, C1-C20 dialkylamino, arylamino, diarylamino, C1-C10 alkylsulfinyl, arylsulfinyl, C1-C10 alkylimino, C1-C10 alkylsulfonimino, arylsulfonyl imino, mercapto, C1-C10 alkylthio, C1-C10 alkylsulfonyl, arylsulfonyl, acylamino, aminoacyl, aminothioacyl, guanidino, ureyl, cyano, acyl, thio acyl, acyloxy, carboxyl and carboxylate groups. On the other hand, cycloalkyl, heterocycloalkyl, heterocycloalkenyl, aryl and heteroaryl may also be fused to each other.
In the present invention, the substitution is mono-substitution or poly-substitution, and the poly-substitution is di-substitution, tri-substitution, tetra-substitution, or penta-substitution. The disubstitution means having two substituents and so on.
The pharmaceutically acceptable salts of the present invention may be salts of anions with positively charged groups on the compounds of formula I. Suitable anions are chloride, bromide, iodide, sulfate, nitrate, phosphate, citrate, methylsulfonate, trifluoroacetate, acetate, malate, tosylate, tartrate, fumarate, glutamate, glucuronate, lactate, glutarate or maleate. Similarly, salts may be formed from cations with negatively charged groups on the compounds of formula I. Suitable cations include sodium, potassium, magnesium, calcium and ammonium ions, such as tetramethylammonium.
In another preferred embodiment, "pharmaceutically acceptable salt" refers to the salt of a compound of formula I with an acid selected from the group consisting of: hydrofluoric acid, hydrochloric acid, hydrobromic acid, phosphoric acid, acetic acid, oxalic acid, sulfuric acid, nitric acid, methanesulfonic acid, sulfamic acid, salicylic acid, trifluoromethanesulfonic acid, naphthalenesulfonic acid, maleic acid, citric acid, acetic acid, lactic acid, tartaric acid, succinic acid, oxalacetic acid, pyruvic acid, malic acid, glutamic acid, p-toluenesulfonic acid, naphthalenesulfonic acid, ethanesulfonic acid, naphthalenedisulfonic acid, malonic acid, fumaric acid, propionic acid, oxalic acid, trifluoroacetic acid, stearic acid, pamoic acid, hydroxymaleic acid, phenylacetic acid, benzoic acid, glutamic acid, ascorbic acid, p-aminobenzenesulfonic acid, 2-acetoxybenzoic acid, isethionic acid, and the like; or a sodium, potassium, calcium, aluminum or ammonium salt of a compound of formula I with an inorganic base; or the methylamine, ethylamine or ethanolamine salt of the compounds of the formula I with organic bases.
Pharmaceutical composition
The invention also provides a pharmaceutical composition comprising an active ingredient in a safe and effective amount, and a pharmaceutically acceptable carrier.
The "active ingredient" described herein refers to the compound of formula I described herein.
The "active ingredient" and the pharmaceutical composition of the invention are used for preparing medicines for treating diseases or symptoms mediated by CDK9-cyclin T1 complex. The "active ingredients" and pharmaceutical compositions of the invention are useful as inhibitors and degradants of the CDK9-cyclin T1 complex.
"safe and effective amount" means: the amount of active ingredient is sufficient to significantly improve the condition without causing serious side effects. Typically, the pharmaceutical compositions contain 1-2000mg of active ingredient per dose, more preferably 10-200mg of active ingredient per dose. Preferably, the "one dose" is a tablet.
"pharmaceutically acceptable carrier" means: one or more compatible solid or liquid filler or gel materials which are suitable for human use and must be of sufficient purity and sufficiently low toxicity. "compatibility" as used herein means that the components of the composition are capable of blending with and between the active ingredients of the present invention without significantly reducing the efficacy of the active ingredients. Examples of pharmaceutically acceptable carrier moieties are cellulose and its derivatives (e.g. sodium carboxymethylcellulose, sodium ethylcellulose, cellulose acetate, etc.), gelatin, talc, solid lubricants (e.g. stearic acid, magnesium stearate), calcium sulphate, vegetable oils (e.g. soybean oil, sesame oil, peanut oil, olive oil, etc.), polyols (e.g. propylene glycol, glycerol, mannitol, sorbitol, etc.), emulsifiers Wetting agents (e.g., sodium lauryl sulfate), coloring agents, flavoring agents, stabilizing agents, antioxidants, preservatives, pyrogen-free water, and the like.
The mode of administration of the active ingredient or pharmaceutical composition of the present invention is not particularly limited, and representative modes of administration include (but are not limited to): oral, intratumoral, rectal, parenteral (intravenous, intramuscular, or subcutaneous), and the like.
Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules.
Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups or tinctures. In addition to the active ingredient, the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, propylene glycol, 1, 3-butylene glycol, dimethylformamide and oils, in particular, cottonseed, groundnut, corn germ, olive, castor and sesame oils or mixtures of these substances and the like. In addition to these inert diluents, the compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
Suspensions, in addition to the active ingredient, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum methoxide and agar or mixtures of these substances, and the like.
Compositions for parenteral injection may comprise physiologically acceptable sterile aqueous or anhydrous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions. Suitable aqueous and nonaqueous carriers, diluents, solvents or excipients include water, ethanol, polyols and suitable mixtures thereof.
The compounds of the invention may be administered alone or in combination with other therapeutic agents, such as antineoplastic agents.
When a pharmaceutical composition is used, a safe and effective amount of the compound of the present invention is applied to a mammal (e.g., a human) in need of treatment, wherein the dose at the time of administration is a pharmaceutically effective dose, and the daily dose is usually 1 to 2000mg, preferably 20 to 500mg, for a human having a body weight of 60 kg. Of course, the particular dosage should also take into account factors such as the route of administration, the health of the patient, etc., which are within the skill of the skilled practitioner.
Example 1: preparation of Compound SNS-032
Step 1:
1-amino-3, 3-dimethylbut-2-one hydrochloride (6.0 g,40mmol,1 eq.) was dissolved in DCM (200 mL), cooled to-5deg.C and triethylamine (22 mL,160mmol,4 eq.) was slowly added. The resulting mixture was cooled to-10 ℃. Chloroacetyl chloride (3.5 mL,44mmol,1.1 eq.) was dissolved in ice DCM (20 mL) and the above mixture was added dropwise over 15 minutes while maintaining the reaction temperature below-5 ℃. The reaction mixture was stirred at-5℃for 2 hours and then quenched with 1N aqueous HCl (100 mL). The phases were separated and the organic phase was washed sequentially with 1N aqueous HCl (100 mL) and water (30 mL), dried (Na 2 SO 4 ) Concentration in vacuo afforded 2-chloro-N- (3, 3-dimethyl-2-oxobutyl) acetamide (2) as a yellow solid (5.5 g, 72%). MS (ESI) 191.97[ M+H ]] + .1H NMR(400MHz,CDCl 3 )δ7.40(brs,1H),4.30(d,J=4.4Hz,2H),4.07(s,2H),1.20(s,9H).
Step 2:
into a 100mL thick-walled pressure-resistant bottle were charged 2-chloro-N- (3, 3-dimethyl-2-oxobutyl) acetamide (2) (8.0 g,41.7mmol,1 eq.) and POCl 3 (16 mL,171.0mmol,4.1 eq.). The reaction mixture was heated to 110 ℃ and stirred overnight. After cooling to room temperature, the reaction mixture was carefully poured into ice water (200 mL). The mixture was extracted with methyl tert-butyl ether (2X 200 mL). The organic extracts were combined and neutralized with saturated sodium bicarbonate to ph=7-8. The organic phase was separated, washed successively with saturated sodium bicarbonate (200 mL), water (200 mL) and NaCl brine (100 mL), dried (Na 2 SO 4 ) Concentrated in vacuo to give 5- (tert-butyl) -2- (chloromethyl) oxazole (3) as a black oil (5.3 g, 73%). MS (ESI) 173.98[ M+H ]] + . 1 H NMR(400MHz,CDCl 3 )δ6.68(s,1H),4.57(s,2H),1.29(s,9H).
Step 3:
5-Bromothiazol-2-amine (4) (3.56 g,20mmol,1 eq.) and potassium thiocyanate (19.4 g,200mmol,10 eq.) are dissolved in methanol (150 mL), heated to 60℃and stirred overnight. The reaction mixture was concentrated in vacuo, then extracted with ethyl acetate (EA, 3×100 mL), washed with NaCl brine, dried (Na 2 SO 4 ) 5-thiocyanothiazole-2-amine (5) was obtained as a yellow solid (2.0 g, 64%). MS (ESI) 157.90[ M+H ]] + .1H NMR(400MHz,CD 3 OD)δ7.33(s,1H).
Step 4:
to a 250mL three-necked round bottom flask was added 5-thiocyanothiazole-2-amine (5) (3.14 g,20mmol,1 eq.) and absolute ethanol (120 mL). NaBH was added in portions under nitrogen 4 (1.5 g,40mmol,2 eq.). The mixture was stirred at room temperature for 1 hour, then acetone (100 mL) was slowly added. After 1 hour, 5- (tert-butyl) -2- (chloromethyl) oxazole (3) (3.8 g,22mmol,1.1 eq.) was dissolved in EtOH (10 mL) and slowly added to the reaction mixture which was heated to 80℃and refluxed for 2 hours. After the reaction was completed, it was cooled to room temperature, concentrated in vacuo, and then extracted with ethyl acetate (3X 100 mL) and NaCl brine (3X 200 mL). The organic phase was separated, dried (Na 2 SO 4 ) Concentrating in vacuum to obtain crude product solid. The crude product was purified by flash chromatography on silica gel (PE: ea=1:1) to give 5- (((5- (tert-butyl) oxazol-2-yl) methyl) thio) thiazol-2-amine (6) as a yellow solid (3.6 g, 67%). MS (ESI) 270.00[ M+H ]] + .1H NMR(400MHz,CDCl 3 )δ6.97(s,1H),6.58(s,1H),5.26(brs,2H),3.88(s,2H),1.26(s,9H).
Step 5:
1- (tert-Butoxycarbonyl) piperidine-4-carboxylic acid (4.58 g,20mmol,2 eq.) was dissolved in DMF (100 mL), HATU (7.6 g,20mmol,2 eq.) and DIPEA (6.95 mL,40mmol,4 eq.) were added and the mixture stirred for 10 min before 5- (((5- (tert-butyl) oxazol-2-yl) methyl) thio) thiazol-2-amine (6) (2.69 g,10mmol,1 eq.) was added. The mixture was stirred at room temperature overnight, after the reaction was completed, water (100 mL) was added to give a large amount of a white solid precipitate, which was washed with water and dried to give tert-butyl 4- ((5- (((5- (tert-butyl) oxazol-2-yl) methyl) thio) thiazol-2-yl) carbamoyl) piperidine-1-carboxylate (7) as a white solid (3.7 g, 77%). MS (ESI) 481.11[ M+H ]] + .1H NMR(400MHz,CDCl 3 )δ7.28(s,1H),6.58(s,1H),4.21–4.08(m,2H),3.95(s,2H),2.89–2.80(m,2H),2.58–2.51(m,1H),1.89–1.83(m,2H),1.80–1.73(m,2H),1.46(s,9H),1.24(s,9H).
Step 6:
/>
tert-butyl 4- ((5- (((5- (tert-butyl) oxazol-2-yl) methyl) thio) thiazol-2-yl) carbamoyl) piperidine-1-carboxylate (7) (2.4 g) was dissolved in EtOH (20 mL), HCl in EtOH (2M, 20 mL) was slowly added and the reaction was stirred at room temperature overnight. The solution was concentrated in vacuo to give the crude product, saturated sodium bicarbonate adjusted ph=7-8, extracted with DCM, concentrated in vacuo and purified by flash chromatography (DCM: meoh=10:1) to give compound SNS-032 as a white solid (1.8 g, 95%). MS (ESI) 381.14[ M+H ] ] + .1H NMR(400MHz,CD 3 OD)δ7.45(s,1H),7.15(s,1H),4.21(s,2H),3.48(dt,J=13.0,3.7Hz,2H),3.12(td,J=12.4,3.0Hz,2H),2.90–2.84(m,1H),2.15–2.09(m,2H),2.00–1.92(m,2H),1.29(s,9H).
Example 2: preparation of Compound LL-K9-001
Step 1:
1-adamantaneacetic acid (48.5 mg,0.25mmol,1 eq.) HATU (114 mg,0.3mmol,1.2 eq.) and DIPEA (173.8. Mu.L, 1mmol,4 eq.) were dissolved in DMF (5 mL), the mixture was stirred for 10 min, then SNS-032 (95 mg,0.25mmol,1 eq.) was added and stirred overnight at room temperature. The reaction solution was extracted with EA and water. The organic phase was separated, washed with NaCl brine and concentrated in vacuo to give a crude product as a solid. The crude product was purified by flash chromatography on silica gel (DCM: meoh=20:1) and the pure fractions were concentrated to give LL-K9-001 (65 mg, 47%) as a white solid. HRMS [ M+H ]] + C 29 H 41 N 4 O 3 S 2 + Calculated as 557.2620, found 577.2664. 1 H NMR(400MHz,CD 3 OD)δ7.32(s,1H),6.68(s,1H),4.62–4.56(m,1H),4.18–4.12(m,1H),3.99(s,2H),3.24–3.16(m,1H),2.79–2.75(m,1H),2.74–2.70(m,1H),2.27(d,J=13.2Hz,1H),2.19(d,J=13.2Hz,1H),2.01–1.86(m,6H),1.74-1.67(m,13H),1.24(s,9H).
Example 3: preparation of Compound LL-K9-002
Prepared from SNS-032 (95 mg,0.25mmol,1 eq.) and (-) -menthoxyacetic acid (53.5 mg,0.25mmol,1 eq.) in the same or similar manner as in example 2. The crude product was purified by flash chromatography on silica gel (DCM: meoh=20:1) followed by semi-preparative HPLC (flow rate, 10mL/min; solvent a MeOH: mecn=1:1; solvent B is 0.1% tfa in water; gradient: eluting from 5% a to 95% a over 30min, 30-45min 95% a) to give LL-K9-002 (95 mg, 66%) as a white solid. HRMS [ M+H ] ] + C 29 H 45 N 4 O 4 S 2 + Calculated as 577.2882, found 577.2931. 1 H NMR(600MHz,DMSO-d 6 )δ12.32(s,1H),7.40(s,1H),6.71(s,1H),4.35–4.27(m,1H),4.18(dd,J=20.5,12.9Hz,1H),4.05(s,2H),4.04–3.97(m,1H),3.95–3.84(m,1H),3.11(qd,J=11.0,3.6Hz,1H),3.05–2.97(m,1H),2.75–2.70(m,1H),2.65–2.56(m,1H),2.21–2.11(m,2H),1.82–1.78(m,2H),1.63–1.54(m,3H),1.44–1.38(m,1H),1.33–1.28(m,1H),1.25–1.22(m,1H),1.16(s,9H),0.97–0.92(m,1H),0.87(dd,J=19.6,6.8Hz,6H),0.83–0.72(m,5H).
Example 4: preparation of Compound LL-K9-003
Step 1:
1-adamantaneacetic acid (1.94 g,10mmol,1 eq.) HATU (4.56 g,12mmol,1.2 eq.) and DIPEA (6.95 mL,40mmol,4 eq.) were dissolved in DMF (50 mL) and the mixture stirred for 10 min before 2, 2-diethoxyethyl-1-amine (1.33 g,10mmol,1 eq.) was added. The mixture was stirred at room temperature overnight and then extracted with EA and water. The organic phase was separated, washed with NaCl brine and concentrated in vacuo to give a crude product as a solid. The crude product was purified by flash chromatography on silica gel (PE: ea=2:1) and the pure fractions were concentrated in vacuo to give 2- ((3 r,5r,7 r) -adamantan-1-yl) -N- (2, 2-diethoxyethyl) acetamide as a white solid (2.2 g, 71%). HRMS [ M+H ]] + C 18 H 32 NO 3 + Calculated as 310.2382, found 310.2390. 1 H NMR(400MHz,CDCl 3 )δ5.61(s,1H),4.47(t,J=5.3Hz,1H),3.73–3.64(m,2H),3.56–3.47(m,2H),3.36(t,J=5.6Hz,2H),1.96–1.91(m,5H),1.70–1.59(m,12H),1.19(t,J=7.1Hz,6H).
Step 2:
2- ((3R, 5R, 7R) -adamantan-1-yl) -N- (2, 2-diethoxyethyl) acetamide (3.1 g,10mmol,1 eq.) was dissolved in MeCN (50 mL), HCl (1N, 50 mL) was added and the mixture stirred overnight at room temperature, then neutralized to pH 7-8 with saturated sodium bicarbonate, extracted with EA and water, na 2 SO 4 Drying and concentration in vacuo afforded 2- ((3R, 5R, 7R) -adamantan-1-yl) -N- (2-oxoethyl) acetamide, which was used without further purification In the next step.
Step 3:
SNS-032 (95 mg,0.25mmol,1 eq.) was dissolved in DCM (10 mL), triethylamine (69. Mu.L, 0.5mmol,2 eq.) and compound 2- ((3R, 5R, 7R) -adamantan-1-yl) -N- (2-oxoethyl) acetamide (117.5 mg,0.5mmol,2 eq.) were added and the mixture stirred for 15min, followed by sodium triacetoxyborohydride (106 mg,0.5mmol,2 eq.). The mixture was stirred at room temperature overnight. The organic phase was then separated by extraction with DCM and water, washed with NaCl brine and concentrated in vacuo to give the crude product. The crude product was purified by flash chromatography on silica gel (DCM: meoh=20:1) followed by semi-preparative HPLC (flow rate, 10mL/min; solvent a MeOH: mecn=1:1; solvent B is 0.1% tfa in water; gradient: eluting from 5% a to 95% a over 30min, 30-45min 95% a) to give LL-K9-003 (99 mg, 66%) as a white solid. HRMS [ M+H ]] + C 31 H 46 N 5 O 3 S 2 + Calculated as 600.3042, found 600.3089. 1 H NMR(400MHz,CD 3 OD)δ7.33(s,1H),6.67(s,1H),3.99(s,2H),3.85–3.72(m,2H),3.56(t,J=6.1Hz,2H),3.28–2.23(m,2H),3.14–3.02(m,2H),2.84–2.74(m,1H),2.22–2.15(m,2H),2.02–1.95(m,6H),1.80–1.61(m,13H),1.25(s,9H).
Example 5: preparation of Compound LL-K9-004
Prepared by the same or similar method as example 4, the structure and characterization data are as follows:
HRMS[M+H] + C 31 H 50 N 5 O 4 S 2 + calculated as 620.3304, found 620.3355. 1 H NMR(600MHz,DMSO-d 6 )δ12.46(s,1H),7.89(t,J=5.6Hz,1H),7.41(s,1H),6.72(s,1H),4.06(s,2H),3.97(d,J=15.0Hz,1H),3.83(d,J=15.0Hz,1H),3.66–3.58(m,2H),3.49–3.46(m,2H),3.19–3.11(m,3H),3.05–2.93(m,2H),2.78–2.71(m,1H),2.22–2.16(m,1H),2.06–2.01(m,3H),1.87–1.78(m,2H),1.64–1.55(m,2H),1.27–1.21(m,2H),1.17(s,9H),0.98–0.90(m,1H),0.88(dd,J=9.4,6.9Hz,6H),0.84–0.78(m,2H),0.74(d,J=6.9Hz,3H).
Example 6: preparation of Compound LL-K9-005
Step 1:
(-) -Bengalenical acid (1.07 g,5mmol,1 eq.) HATU (2.28 g,6mmol,1.2 eq.) and DIPEA (3.5 mL,20mmol,4 eq.) were dissolved in DMF (20 mL) and the mixture stirred for 10 min. 4-aminobutan-1-ol (445 mg,5mmol,1 eq.) was added and the mixture stirred at room temperature overnight. The organic phase was then separated by EA and water extraction, washed with NaCl brine and concentrated in vacuo to give the crude product. The crude product was purified by flash chromatography on silica gel (PE: ea=1:4) and the pure fractions were concentrated in vacuo to give N- (4-hydroxybutyl) -2- (((1 r,2s,5 r) -2-isopropyl-5-methylcyclohexyl) oxy) acetamide as a yellow oil (1.03 g, 72%). HRMS [ M+H ]] + C 16 H 32 NO 3 + Calculated as 286.2382, found 286.2386. 1 H NMR(400MHz,CDCl 3 )δ6.72(s,1H),4.05(d,J=15.1Hz,1H),3.84(d,J=15.1Hz,1H),3.67(t,J=5.7Hz,2H),3.33(q,J=6.4Hz,2H),3.13(td,J=10.6,4.1Hz,1H),2.11–2.00(m,2H),1.69–1.56(m,6H),1.41–1.27(m,2H),1.02–0.94(m,1H),0.92–0.81(m,8H),0.77(d,J=7.0Hz,3H).
Step 2:
n- (4-hydroxybutyl) -2- (((1R, 2S, 5R) -2-isopropyl-5-methylcyclohexyl) oxy) acetamide (560 mg,2mmol,1 eq.) was dissolved in DCM (10 mL) and addedNEt 3 (554. Mu.L, 4mmol,2 eq.). The mixture was cooled to 0deg.C, and methanesulfonic anhydride (697 mg,4mmol,2 eq.) was dissolved in DCM (4 mL) and added dropwise to the reaction. The mixture was stirred at room temperature overnight, then extracted with DCM and water, washed with NaCl brine, na 2 SO 4 Drying and concentration in vacuo afforded butyl 4- (2- (((1R, 2S, 5R) -2-isopropyl-5-methylcyclohexyl) oxy) acetamido) methanesulfonate as a yellow oil (640 mg, 88%) which was used in the next step without further purification. HRMS [ M+H ] ] + C 17 H 34 NO 5 S + Calculated as 364.2158, found 364.2166. 1 H NMR(400MHz,CDCl 3 )δ6.65(s,1H),4.22(t,J=6.2Hz,2H),4.02(d,J=15.1Hz,1H),3.81(d,J=15.1Hz,1H),3.30(dd,J=13.4,6.8Hz,2H),3.11(td,J=10.5,4.0Hz,1H),2.98(s,3H),2.11–2.04(m,1H),2.03–1.98(m,1H),1.80–1.71(m,2H),1.67–1.57(m,4H),1.37–1.23(m,2H),1.00–0.92(m,1H),0.88(d,J=6.8Hz,6H),0.85–0.79(m,2H),0.74(d,J=7.0Hz,3H).
Step 3:
SNS-032 (95 mg,0.25mmol,1 eq.) was dissolved in DMF (3 mL) and NEt was added 3 (69. Mu.L, 0.5mmol,2 eq.) and butyl 4- (2- (((1R, 2S, 5R) -2-isopropyl-5-methylcyclohexyl) oxy) acetamido) methanesulfonate (181.5 mg,0.5mmol,2 eq.). The mixture was heated to 80 ℃, stirred overnight, then extracted with EA and water, the organic phase separated, washed with NaCl brine and concentrated in vacuo to afford a crude product as a solid. The crude product was purified by flash chromatography on silica gel (DCM: meoh=20:1) and the pure fractions were concentrated in vacuo to afford LL-K9-005 (68 mg, 42%) as a yellow solid. HRMS [ M+H ]] + C 33 H 54 N 5 O 4 S 2 + Calculated as 648.3617, found 648.3671. 1 H NMR(600MHz,DMSO-d 6 )δ12.27(s,1H),7.50(t,J=5.9Hz,1H),7.37(s,1H),6.71(s,1H),4.04(s,2H),3.90(d,J=14.7Hz,1H),3.77(d,J=14.7Hz,1H),3.13–3.09(m,3H),2.97–2.84(m,2H),2.49–2.43(m,1H),2.42–2.21(m,2H),2.20–2.14(m,1H),2.04–2.01(m,1H),1.98–1.91(m,1H),1.79–1.73(m,2H),1.65–1.58(m,3H),1.57–1.53(m,1H),1.43–1.39(m,4H),1.34–1.29(m,1H),1.27–1.19(m,2H),1.16(s,9H),0.96–0.89(m,1H),0.86(dd,J=8.6,6.9Hz,6H),0.82–0.77(m,2H),0.73(d,J=6.9Hz,3H).
Example 7: preparation of LL-K9-006
Prepared by the same or similar methods as example 6, intermediate and final product structures and characterization data are as follows:
alcohol intermediates
N- (6-hydroxyhexyl) -2- (((1R, 2S, 5R) -2-isopropyl-5-methylcyclohexyl) oxy) acetamide. HRMS [ M+H ]] + C 18 H 36 NO 3 + Calculated as 314.2695, found 314.2701. 1 H NMR(400MHz,CDCl 3 )δ6.62(s,1H),4.05(d,J=15.1Hz,1H),3.83(d,J=15.1Hz,1H),3.62(t,J=6.5Hz,2H),3.28(dd,J=13.4,6.7Hz,2H),3.13(td,J=10.6,4.0Hz,1H),2.14–1.99(m,2H),1.68–1.48(m,6H),1.43–1.26(m,6H),1.03–0.93(m,1H),0.92–0.80(m,8H),0.77(d,J=7.0Hz,3H).
Methanesulfonyl intermediates/>
6- (2- ((1R, 2S, 5R) -2-isopropyl-5-methylcyclohexyl) oxy) acetamido methyl sulfonate. HRMS [ M+H ]] + C 19 H 38 NO 5 S + Calculated as 392.2471, found 392.2484. 1 H NMR(400MHz,CDCl 3 )δ6.66(s,1H),4.22(t,J=6.5Hz,2H),4.07(d,J=15.2Hz,1H),3.86(d,J=15.2Hz,1H),3.29(dd,J=13.4,6.8Hz,2H),3.14(td,J=10.5,4.0Hz,1H),3.00(s,3H),2.15–1.99(m,2H),1.80–1.71(m,2H),1.69–1.61(m,2H),1.58–1.50(m,2H),1.48–1.30(m,6H),1.03–0.95(m,1H),0.92(d,J=6.8Hz,6H),0.88–0.82(m,2H),0.78(d,J=7.0Hz,3H).
LL-K9-06
HRMS[M+H] + C 35 H 58 N 5 O 4 S 2 + Calculated as 676.3930, found 676.3984. 1 H NMR(600MHz,DMSO-d 6 )δ12.46(s,1H),7.50(t,J=5.8Hz,1H),7.41(s,1H),6.72(s,1H),4.06(s,2H),3.90(d,J=14.7Hz,1H),3.78(d,J=14.7Hz,1H),3.57–3.53(m,2H),3.13(dd,J=10.7,4.1Hz,1H),3.09(d,J=6.6Hz,2H),3.05–3.01(m,2H),2.96–2.88(m,2H),2.74(tt,J=12.1,3.4Hz,1H),2.20–2.15(m,1H),2.06–2.00(m,3H),1.87–1.77(m,2H),1.63–1.55(m,4H),1.44–1.40(m,2H),1.28–1.22(m,6H),1.17(s,9H),0.93(qd,J=13.0,3.3Hz,1H),0.89–0.86(m,6H),0.83–0.78(m,2H),0.74(d,J=7.0Hz,3H).
Example 8: preparation of LL-K9-007
Prepared by the same or similar methods as example 6, intermediate and final product structures and characterization data are as follows:
alcohol intermediates
N- (2- (2-hydroxyethoxy) ethoxy) ethyl) -2- ((1 r,2s,5 r) -2-isopropyl-5-methylcyclohexyl) acetamide. HRMS [ M+H ]] + C 18 H 36 NO 5 + Calculated as 346.2594, found 346.2602. 1 H NMR(400MHz,CDCl 3 )δ7.00(s,1H),4.07(d,J=15.2Hz,1H),3.86(d,J=15.2Hz,1H),3.76–3.72(m,2H),3.65–3.57(m,8H),3.54–3.45(m,2H),3.14(td,J=10.6,4.0Hz,1H),2.16–2.09(m,1H),2.06–2.01(m,1H),1.69–1.60(m,2H),1.40–1.26(m,2H),1.03–0.94(m,1H),0.93–0.81(m,8H),0.77(d,J=7.0Hz,3H).
Methanesulfonyl intermediates
2- (2- (2- ((1R, 2S, 5R) -2-isopropyl-5-A)Methylcyclohexyl) oxy) acetamido) ethoxy) ethyl methanesulfonate. HRMS [ M+H ]] + C 19 H 38 NO 7 S + Calculated as 424.2369, found 424.2382. 1 H NMR(400MHz,CDCl 3 )δ6.95(s,1H),4.40–4.33(m,2H),4.06(d,J=15.2Hz,1H),3.84(d,J=15.2Hz,1H),3.78–3.73(m,2H),3.67–3.59(m,4H),3.58–3.52(m,2H),3.51–3.45(m,2H),3.13(td,J=10.6,4.1Hz,1H),3.05(s,3H),2.16–2.06(m,1H),2.06–2.00(m,1H),1.69–1.59(m,2H),1.35–1.26(m,2H),1.02–0.93(m,1H),0.92–0.88(m,6H),0.88–0.81(m,2H),0.76(d,J=7.0Hz,3H).
LL-K9-007
HRMS[M+H] + C 35 H 58 N 5 O 6 S 2 + Calculated as 708.3829, found 708.3886. 1 H NMR(600MHz,DMSO-d 6 )δ12.48(s,1H),7.49(t,J=5.8Hz,1H),7.40(s,1H),6.71(s,1H),4.05(s,2H),3.92(d,J=14.8Hz,1H),3.79(d,J=14.8Hz,1H),3.76–3.74(m,2H),3.58–3.53(m,6H),3.44(t,J=6.0Hz,2H),3.30–3.25(m,4H),3.11(td,J=10.6,4.0Hz,1H),3.05–2.95(m,2H),2.73(tt,J=12.1,3.4Hz,1H),2.18–2.13(m,1H),2.04–2.00(m,3H),1.92–1.82(m,2H),1.62–1.58(m,1H),1.57–1.53(m,1H),1.33–1.28(m,1H),1.23–1.20(m,1H),1.16(s,9H),0.94–0.88(m,1H),0.87–0.84(m,6H),0.81–0.76(m,2H),0.72(d,J=6.9Hz,3H).
Example 9: preparation of LL-K9-008
Prepared by the same or similar methods as example 6, intermediate and final product structures and characterization data are as follows:
alcohol intermediates
1- (4- (hydroxymethyl) piperidin-1-yl) -2- ((1 r,2s,5 r) -2-isopropyl-5-methylcyclohexyl) oxy) ethan-1-one. HRMS [ M+H ]] + C 18 H 34 NO 3 + Calculated as 312.2539, found 312.2547. 1 H NMR(400MHz,CDCl 3 )δ4.62–4.50(m,1H),4.19(dd,J=12.6,3.1Hz,1H),4.09–3.95(m,2H),3.54–3.43(m,2H),3.20–3.10(m,1H),3.05–2.95(m,1H),2.62–2.50(m,1H),2.26–2.06(m,2H),1.83–1.70(m,3H),1.66–1.56(m,2H),1.38–1.28(m,1H),1.25–1.13(m,3H),1.00–0.92(m,1H),0.88(dd,J=8.0,7.0Hz,6H),0.85–0.77(m,2H),0.74(dd,J=9.8,7.0Hz,3H).
Methanesulfonyl intermediates
(1- (2- ((1 r,2s,5 r) -2-isopropyl-5-methylcyclohexyl) oxy) acetyl) piperidin-4-yl) methyl methanesulfonate. HRMS [ M+H ]] + C 19 H 36 NO 5 S + Calculated as 390.2314, found 390.2326. 1 H NMR(400MHz,CDCl 3 )δ4.63–4.54(m,1H),4.19(dd,J=12.7,2.8Hz,1H),4.11–3.99(m,4H),3.17–3.03(m,1H),3.00(s,3H),2.62–2.51(m,1H),2.21–1.96(m,3H),1.84–1.74(m,2H),1.64–1.56(m,2H),1.35–1.20(m,4H),1.00–0.91(m,1H),0.90–0.85(m,6H),0.83–0.77(m,2H),0.76–0.70(m,3H).
LL-K9-008:
HRMS[M+H] + C 35 H 56 N 5 O 4 S 2 + Calculated as 674.3774, found 674.3827. 1 H NMR(600MHz,DMSO-d 6 )δ12.46(s,1H),7.41(s,1H),6.72(s,1H),4.30(t,J=14.3Hz,1H),4.17(d,J=12.8Hz,1H),4.06(s,2H),3.99(dd,J=12.8,4.9Hz,1H),3.91–3.81(m,2H),3.62–3.58(m,2H),3.14–3.07(m,1H),3.00–2.96(m,3H),2.96–2.90(m,2H),2.74(tt,J=12.0,3.6Hz,1H),2.60–2.53(m,1H),2.20–2.00(m,6H),1.95–1.87(m,2H),1.77–1.73(m,2H),1.63–1.59(m,1H),1.57–1.54(m,1H),1.33–1.29(m,1H),1.24–1.22(m,1H),1.17(s,9H),0.96–0.91(m,1H),0.88(d,J=6.5Hz,3H),085 (d, j=7.0 hz, 3H), 0.83-0.78 (m, 1H), 0.75-0.70 (m, 4H). Example 10: preparation of LL-K9-009
Prepared by the same or similar methods as example 6, intermediate and final product structures and characterization data are as follows:
alcohol intermediates
N- (2- (2-hydroxyethoxy) ethyl) -2- ((1R, 2S, 5R) -2-isopropyl-5-methylcyclohexyl) oxy) acetamide. HRMS [ M+H ]] + C 16 H 32 NO 4 + Calculated as 302.2331, found 302.2339. 1 H NMR(400MHz,CDCl 3 )δ6.97(s,1H),4.07(d,J=15.2Hz,1H),3.85(d,J=15.2Hz,1H),3.76–3.70(m,2H),3.61–3.54(m,4H),3.53–3.47(m,2H),3.14(td,J=10.6,4.0Hz,1H),2.13–2.08(m,1H),2.06–2.01(m,1H),1.68–1.60(m,2H),1.38–1.26(m,2H),1.03–0.94(m,1H),0.91(d,J=6.7Hz,6H),0.88–0.81(m,2H),0.77(d,J=7.0Hz,3H).
Methanesulfonyl intermediates
Ethyl 2- (2- (2- ((1 r,2s,5 r) -2-isopropyl-5-methylcyclohexyl) oxy) acetamido) ethoxy) methylsulfonate. HRMS [ M+H ]] + C 17 H 34 NO 6 S + Calculated as 380.2107, found 380.2114. 1 H NMR(400MHz,CDCl 3 )δ6.92(s,1H),4.38–4.33(m,2H),4.06(d,J=15.2Hz,1H),3.85(d,J=15.2Hz,1H),3.77–3.71(m,2H),3.63–3.56(m,2H),3.55–3.45(m,2H),3.14(td,J=10.7,4.1Hz,1H),3.05(s,3H),2.13–2.08(m,1H),2.06–2.01(m,1H),1.68–1.60(m,2H),1.40–1.30(m,2H),1.00–0.94(m,1H),0.91(d,J=6.8Hz,6H),0.86–0.82(m,2H),0.77(d,J=7.0Hz,3H).
LL-K9-009
HRMS[M+H] + C 33 H 54 N 5 O 5 S 2 + Calculated as 664.3566, found 664.3618. 1 H NMR(600MHz,DMSO-d 6 )δ12.24(s,1H),7.37(s,1H),6.71(s,1H),4.04(s,2H),3.92(d,J=14.8Hz,1H),3.79(d,J=14.9Hz,1H),3.49(t,J=5.9Hz,2H),3.42(t,J=5.8Hz,2H),3.29–3.24(m,2H),3.12(td,J=10.6,4.0Hz,1H),2.94–2.87(m,2H),2.48–2.44(m,2H),2.44–2.39(m,1H),2.19–2.13(m,1H),2.05–2.01(m,1H),2.01–1.92(m,2H),1.76–1.70(m,2H),1.62–1.54(m,4H),1.35–1.28(m,1H),1.23–1.21(m,1H),1.16(s,9H),0.97–0.89(m,1H),0.87–0.85(m,6H),0.82–0.77(m,2H),0.73(d,J=7.0Hz,3H).
Example 11: preparation of LL-K9-010
Step 1:
1-adamantaneacetic acid (0.97 g,5mmol,1 eq.) HATU (2.28 g,6mmol,1.2 eq.) and DIPEA (3.5 mL,20mmol,4 eq.) were dissolved in DMF (20 mL) and the mixture stirred for 10 min. 4-aminobutan-1-ol (445 mg,5mmol,1 eq.) was added and the mixture stirred at room temperature overnight. The organic phase was then separated by EA and water extraction, washed with NaCl brine and concentrated in vacuo to give the crude product. The crude product was purified by flash chromatography on silica gel (PE: ea=1:4) and the pure fractions were concentrated in vacuo to give 2- ((3 r,5r,7 r) -adamantan-1-yl) -N- (4-hydroxybutyl) acetamide as a yellow oil (1.1 g, 83%). MS (ESI) 266.23[ M+H ] ] + .1H NMR(600MHz,CDCl 3 )δ5.73(s,1H),3.68–3.65(m,2H),3.28–3.24(m,2H),1.96–1.89(m,5H),1.70–1.66(m,3H),1.63–1.58(m,13H).
Step 2:
2- ((3R, 5R, 7R) -adamantan-1-yl) -N- (4-hydroxybutyl) acetamide (530 mg,2mmol,1 eq.) was dissolved in DCM (10 mL) and addedNEt 3 (554. Mu.L, 4mmol,2 eq.). The mixture was cooled to 0deg.C, and methanesulfonic anhydride (697 mg,4mmol,2 eq.) was dissolved in DCM (4 mL) and added dropwise to the reaction. The mixture was stirred at room temperature overnight, then extracted with DCM and water, washed with NaCl brine, na 2 SO 4 Drying and concentration in vacuo afforded butyl 4- (2- ((3 r,5r,7 r) -adamantan-1-yl) acetamido) methylsulfonate as a yellow oil (560 mg, 86%) which was used in the next step without further purification. MS (ESI) 344.45[ M+H ]] + .1H NMR(600MHz,CDCl 3 )δ5.64(s,1H),4.24(t,J=6.3Hz,2H),3.26(dd,J=13.1,6.9Hz,2H),3.00(s,3H),1.95–1.89(m,5H),1.79–1.75(m,2H),1.69–1.65(m,3H),1.62–1.58(m,11H).
Step 3:
SNS-032 (95 mg,0.25mmol,1 eq.) was dissolved in DMF (3 mL) and NEt was added 3 (69. Mu.L, 0.5mmol,2 eq.) and butyl 4- (2- ((3R, 5R, 7R) -adamantan-1-yl) acetamido) methylsulfonate (171.5 mg,0.5mmol,2 eq.). The mixture was heated to 80 ℃, stirred overnight, then extracted with EA and water, the organic phase separated, washed with NaCl brine and concentrated in vacuo to afford a crude product as a solid. The crude product was purified by flash chromatography on silica gel (DCM: meoh=20:1) and concentrated in vacuo to afford LL-K9-010 (64 mg, 41%) as a yellow solid. HRMS [ M+H ] ] + C 33 H 50 N 5 O 3 S 2 + Calculated as 628.3355, found 628.3408. 1 H NMR(400MHz,DMSO-d 6 )δ12.24(s,1H),7.67(t,J=5.5Hz,1H),7.38(s,1H),6.72(s,1H),4.04(s,2H),3.04–2.99(m,2H),2.92–2.85(m,2H),2.46–2.41(m,1H),2.31–2.21(m,2H),1.91–1.80(m,7H),1.77–1.72(m,2H),1.67–1.54(m,14H),1.43–1.35(m,4H),1.16(s,9H).
Example 12: preparation of LL-K9-011
Prepared by the same or similar methods as example 11, intermediate and final product structures and characterization data are as follows:
alcohol intermediates
2- ((3 r,5r,7 r) -adamantan-1-yl) -N- (6-hydroxyhexyl) acetamide. MS (ESI) 294.45[ M+H ]] + .1H NMR(600MHz,CDCl 3 )δ5.49(s,1H),3.63–3.60(m,2H),3.24–3.20(m,2H),1.96–1.89(m,5H),1.70–1.66(m,3H),1.63–1.59(m,9H),1.56–1.48(m,4H),1.40–1.32(m,4H).
Methanesulfonyl intermediates
6- (2- ((3R, 5R, 7R) -adamantan-1-yl) acetamido) methylsulfonic acid hexyl ester
MS(ESI)372.31[M+H] + .1H NMR(600MHz,CDCl 3 )δ5.47(s,1H),4.21(t,J=6.5Hz,2H),3.24–3.19(m,2H),2.99(s,3H),1.96–1.89(m,5H),1.75–1.72(m,2H),1.69–1.66(m,3H),1.63–1.59(m,9H),1.52–1.47(m,2H),1.43–1.40(m,2H),1.37–1.33(m,2H).
LL-K9-011
HRMS[M+H] + C 35 H 54 N 5 O 3 S 2 + Calculated as 656.3668, found 656.3720. 1 H NMR(400MHz,DMSO-d 6 )δ12.25(s,1H),7.65(t,J=5.5Hz,1H),7.38(s,1H),6.72(s,1H),4.04(s,2H),3.02–2.89(m,4H),2.47–2.41(m,1H),2.35–2.23(m,2H),1.92–1.79(m,7H),1.78–1.72(m,2H),1.66–1.54(m,14H),1.41–1.35(m,4H),1.27–1.23(m,4H),1.17(s,9H).
Example 13: preparation of LL-K9-012
Prepared by the same or similar methods as example 11, intermediate and final product structures and characterization data are as follows:
alcohol intermediates
2- ((3R, 5R, 7R) -adamantan-1-yl) -N- (2- (2- (2-hydroxyethoxy) ethoxy) acetamide MS (ESI) 326.23[ M+H)] + . 1 H NMR(600MHz,CDCl 3 )δ6.30(s,1H),3.69–3.67(m,2H),3.61–3.59(m,2H),3.58–3.54(m,4H),3.51–3.48(m,2H),3.39–3.36(m,2H),1.91–1.87(m,5H),1.65–1.61(m,3H),1.58–1.54(m,9H).
Methanesulfonyl intermediates
Ethyl 2- (2- (2- (2- ((3R, 5R, 7R) adamantan-1-yl) acetamido) ethoxy) methanesulfonate MS (ESI) 404.20[ M+H)] + . 1 H NMR(600MHz,CDCl 3 )δ5.88(s,1H),4.38–4.36(m,2H),3.77–3.75(m,2H),3.66–3.64(m,2H),3.61–3.59(m,2H),3.54–3.51(m,2H),3.44–3.41(m,2H),3.06(s,3H),1.95–1.92(m,5H),1.69–1.67(m,3H),1.62–1.59(m,9H).
LL-K9-012
HRMS[M+H] + C 35 H 54 N 5 O 5 S 2 + Calculated as 688.3566, found 688.3622. 1 H NMR(600MHz,DMSO-d 6 )δ12.46(s,1H),7.75(t,J=5.6Hz,1H),7.41(s,1H),6.72(s,1H),4.06(s,2H),3.75–3.73(m,2H),3.59–3.56(m,4H),3.55–3.53(m,2H),3.40–3.38(m,2H),3.30–3.26(m,2H),3.19–3.16(m,2H),3.04–2.96(m,2H),2.73(tt,J=12.2,3.5Hz,1H),2.07–2.01(m,2H),1.90–1.81(m,7H),1.65–1.62(m,3H),1.56–1.52(m,9H),1.17(s,9H).
Example 14: preparation of LL-K9-013
Prepared by the same or similar methods as example 11, intermediate and final product structures and characterization data are as follows:
alcohol intermediates
2- ((3 s) -adamantan-1-yl) -1- (4- (hydroxymethyl) piperidin-1-yl) ethan-1-one. MS (ESI) 292.43[ M+H ] ] + . 1 H NMR(600MHz,CDCl 3 )δ4.66–4.61(m,1H),3.96–3.91(m,1H),3.47–3.90(m,2H),2.96(td,J=13.2,2.7Hz,1H),2.48(td,J=12.9,2.6Hz,1H),2.14(d,J=13.3Hz,1H),2.07(d,J=13.3Hz,1H),1.92–1.89(m,3H),1.79–1.75(m,1H),1.74–1.66(m,2H),1.65–1.62(m,3H),1.60–1.56(m,9H),1.15–1.03(m,2H).
Methanesulfonyl intermediates/>
(1- (2- ((3 s) -adamantan-1-yl) acetyl) piperidin-4-yl) methyl methanesulfonate. MS (ESI) 370.52[ M+H ]] + . 1 H NMR(600MHz,CDCl 3 )δ4.72–4.69(m,1H),4.06–4.02(m,2H),4.00-3.96(m,1H),2.98(s,3H),2.58–2.45(m,2H),2.14(d,J=13.4Hz,1H),2.08(d,J=13.4Hz,1H),1.99–1.94(m,1H),1.93–1.91(m,3H),1.82–1.78(m,1H),1.76–1.73(m,1H),1.66–1.63(m,3H),1.61–1.58(m,9H),1.20–1.12(m,2H).
LL-K9-013
HRMS[M+H] + C 35 H 52 N 5 O 3 S 2 + Calculated as 654.3512, found 654.3564. 1 H NMR(400MHz,DMSO-d 6 )δ12.45(s,1H),7.41(s,1H),6.72(s,1H),4.47–4.42(m,1H),4.06(s,2H),4.02–3.96(m,1H),3.63–3.55(m,2H),3.03–2.91(m,4H),2.76–2.69(m,1H),2.10–2.08(m,1H),2.05–1.98(m,3H),1.93–1.88(m,4H),1.77–1.70(m,2H),1.68–1.55(m,14H),1.27–1.22(m,4H),1.18(s,9H).
Example 15: preparation of LL-K9-014
Prepared by the same or similar methods as example 11, intermediate and final product structures and characterization data are as follows:
alcohol intermediates
2- ((3 r,5r,7 r) -adamantan-1-yl) -N- (2- (2-hydroxyethoxy) ethyl) acetamide. MS (ESI) 282.20[ M+H ]] + . 1 H NMR(600MHz,CDCl 3 )δ6.42(t,J=5.6Hz,1H),3.69–3.67(m,2H),3.52–3.49(m,4H),3.41–3.37(m,2H),1.92–1.89(m,5H),1.65–1.62(m,3H),1.58–1.55(m,9H).
Methanesulfonyl intermediates
Ethyl 2- (2- (2- ((3 r,5r,7 r) -adamantan-1-yl) acetamido) ethoxy) methylsulfonate. MS (ESI) 360.18[ M+H ]] + . 1 H NMR(600MHz,CDCl 3 )δ6.07(t,J=4.9Hz,1H),4.33–4.31(m,2H),3.68–3.66(m,2H),3.52(t,J=5.2Hz,2H),3.40–3.36(m,2H),3.01(s,3H),1.91–1.88(m,5H),1.65–1.62(m,3H),1.58–1.55(m,9H).
LL-K9-014
HRMS[M+H] + C 33 H 50 N 5 O 4 S 2 + Calculated as 644.3304, found 644.3353. 1 H NMR(400MHz,DMSO-d 6 )δ12.24(s,1H),7.72(t,J=5.5Hz,1H),7.38(s,1H),6.71(s,1H),4.04(s,2H),3.48(t,J=5.5Hz,2H),3.20–3.15(m,2H),2.94–2.87(m,2H),2.48–2.39(m,3H),1.98–1.80(m,9H),1.76–1.71(m,2H),1.66–1.54(m,14H),1.16(s,9H).
Example 16: preparation of LL-K9-015
Step 1:
SNS-032 (3.8 g,10mmol,1 eq.) was dissolved in DCM (40 mL) and NEt was added 3 (5.5 mL,40mmol,4 eq.) the mixture was cooled to-40 ℃. Ethyl chloride-1-sulfonyl chloride (2.1 mL,20mmol,2 eq.) was dissolved in ice DCM (4 mL) and added dropwise to the reaction solution. The mixture was stirred at-40 ℃ for 2 hours, then quenched with water, extracted with DCM and water, washed with NaCl brine and concentrated in vacuo to give the crude product as a solid. The crude product was purified by flash chromatography on silica gel (DCM: meoh=40:1) and the pure fractions were concentrated to give N- (5- (((5- (tert-butyl) oxazol-2-yl) methyl) thio) thiazol-2-yl) -1- (vinylsulfonyl) piperidine-4-carboxamide as a yellow solid (2.2 g, 47%). HRMS [ M+H ] ] + C 19 H 27 N 4 O 4 S 3 + Calculated as 471.1194, found 471.1210. 1 H NMR(400MHz,CD 3 OD)δ7.32(s,1H),6.69–6.62(m,2H),6.19(d,J=16.6Hz,1H),6.12(d,J=10.0Hz,1H),3.99(s,2H),3.72(dt,J=12.8,3.6Hz,2H),2.76(td,J=12.1,2.8Hz,2H),2.58(tt,J=11.2,3.9Hz,1H),1.98–1.92(m,2H),1.86–1.77(m,2H),1.25(s,9H).
Step 2:
n- (5- (((5- (tert-butyl) oxazol-2-yl) methyl) thio) thiazol-2-yl) -1- (vinylsulfonyl) piperidine-4-carboxamide (2.35 g,5mmol,1 eq.) was dissolved in MeCN (100 mL) and Cs was added 2 CO 3 (3.25 g,10mmol,2 eq.) and NH 4 OH (48%, 40 mL). The reaction was stirred at room temperature overnight and then concentrated in vacuo. The mixture was extracted with DCM and water, washed with NaCl brine and concentrated in vacuo to give the crude product as a solid. The crude product was purified by flash chromatography on silica gel (DCM: meoh=20:1) and the pure fractions were concentrated in vacuo to give 1- ((2-aminoethyl) sulfonyl) -N- (5- (((5- (tert-butyl)) oxazol-2-yl) methyl) thio) thiazol-2-yl) piperidine-4-carboxamide as a yellow solid (1.8 g, 75%). HRMS [ M+H ]] + C 19 H 30 N 5 O 4 S 3 + Calculated as 488.1460, found 488.1479. 1 H NMR(400MHz,DMSO-d 6 )δ7.38(s,1H),6.71(s,1H),4.04(s,2H),3.66–3.58(m,2H),3.12(t,J=6.9Hz,2H),2.91(t,J=6.9Hz,2H),2.87–2.79(m,2H),2.66–2.58(m,1H),1.91–1.86(m,2H),1.64–1.54(m,2H),1.17(s,9H).
Step 3:
(-) -Bengalenical acid (53.5 mg,0.25mmol,1 eq.) is dissolved in DMF (5 mL), HATU (114 mg,0.3mmol,1.2 eq.) and DIPEA (173.8. Mu.L, 1mmol,4 eq.) are added, the mixture is stirred for 10 min, then 1- ((2-aminoethyl) sulfonyl) -N- (5- (((5- (tert-butyl)) oxazol-2-yl) methyl) thio) thiazol-2-yl) piperidine-4-carboxamide (122 mg,0.25mmol,1 eq.) is added and the mixture is stirred overnight at room temperature, then extracted with EA and water, washed with NaCl brine and concentrated in vacuo to give the crude product as a solid. The crude product was purified by flash chromatography on silica gel (DCM: meoh=20:1) followed by semi-preparative HPLC (flow rate, 10mL/min; solvent a MeOH: mecn=1:1; solvent B is 0.1% tfa in water; gradient: eluting from 5% a to 95% a over 30min, 30-45min 95% a) to give LL-K9-015 (102 mg, 60%) as a white solid. HRMS [ M+H ] ] + C 31 H 50 N 5 O 6 S 3 + Calculated as 684.2923, found 684.2989. 1 H NMR(400MHz,CD 3 OD)δ7.32(s,1H),6.68(s,1H),4.08(d,J=15.3Hz,1H),3.99(s,2H),3.90(d,J=15.2Hz,1H),3.84–3.78(m,2H),3.69(td,J=6.5,1.5Hz,2H),3.25(t,J=6.6Hz,2H),3.21(dd,J=10.7,4.2Hz,1H),2.95(td,J=12.2,2.5Hz,2H),2.63(tt,J=11.2,3.7Hz,1H),2.29–2.21(m,1H),2.13–2.07(m,1H),1.99–1.92(m,2H),1.86–1.75(m,2H),1.72–1.63(m,2H),1.36–1.28(m,2H),1.25(s,9H),1.09–0.98(m,1H),0.96–0.87(m,8H),0.80(d,J=7.0Hz,3H).
Example 17: preparation of LL-K9-016
1-adamantaneacetic acid (48.5 mg,0.25mmol,1 eq) was dissolved in DMF (5 mL), HATU (114 mg,0.3mmol,1.2 eq) and DIPEA (173.8. Mu.L, 1mmol,4 eq) were added, the mixture was stirred for 10 min, then the compound 1- ((2-aminoethyl) sulfonyl) -N- (5- (((5- (tert-butyl)) oxazol-2-yl) methyl) thio) thiazol-2-yl) piperidine-4-carboxamide (122 mg,0.25mmol,1 eq) was added and the mixture stirred overnight at room temperature, then extracted with EA and water, washed with NaCl brine and concentrated in vacuo to give the crude product as a solid. The crude product was purified by flash chromatography on silica gel (DCM: meoh=20:1) and the pure fractions were concentrated to give LL-K9-016 as a white solid (107 mg, 66%). HRMS [ M+H ]] + C 31 H 46 N 5 O 5 S 3 + Calculated as 664.2661, found 664.2721. 1 H NMR(400MHz,CD 3 OD)δ7.32(s,1H),6.68(s,1H),3.99(s,2H),3.80(dt,J=12.2,3.0Hz,2H),3.57(t,J=6.8Hz,2H),3.21(t,J=6.8Hz,2H),2.95(td,J=12.2,2.6Hz,2H),2.63(tt,J=11.2,3.7Hz,1H),1.99–1.91(m,7H),1.85–1.63(m,14H),1.25(s,9H).
Example 18: preparation of LL-K9-017
1- ((2-aminoethyl) sulfonyl) -N- (5- (((5- (tert-butyl)) oxazol-2-yl) methyl) thio) thiazol-2-yl) piperidine-4-carboxamide (122 mg,0.25mmol,1 eq) and 2-isocyanatoadamantane (44 mg,0.25mmol,1 eq) were dissolved in DCM (10 mL) and the mixture stirred overnight at room temperature then extracted with DCM and water, washed with NaCl brine and concentrated in vacuo to give the crude product as a solid. The crude product was purified by flash chromatography on silica gel (DCM: meoh=20:1) and the pure fractions were concentrated in vacuo to give LL-K9-017 as a white solid (98 mg, 59%). HRMS [ M+H ] ] + C 30 H 45 N 6 O 5 S 3 + Calculated as 665.2614, found 665.2670. 1 H NMR(400MHz,CD 3 OD)δ7.32(s,1H),6.68(s,1H),3.99(s,2H),3.82–3.76(m,2H),3.49(t,J=6.4Hz,2H),3.17(t,J=6.4Hz,2H),2.96–2.89(m,2H),2.62(tt,J=11.2,3.8Hz,1H),2.03–1.92(m,10H),1.85–1.69(m,9H),1.25(s,9H).
Example 19: preparation of LL-K9-018
1- ((2-aminoethyl) sulfonyl) -N- (5- (((5- (tert-butyl)) oxazol-2-yl) methyl) thio) thiazol-2-yl) piperidine-4-carboxamide (122 mg,0.25mmol,1 eq.) N5- [ bis [ [ (1, 1-dimethylethoxy) carbonyl []Amino group]Methylene group]-N2- [ (1, 1-dimethylethoxy) carbonyl ]]L-ornithine (119 mg,0.25mmol,1 eq.) N-methylimidazole (NMI) (60. Mu.L) was dissolved in MeCN (10 mL), stirred at room temperature for 10min, then tetramethyl chlorourea hexafluorophosphate (TCFH) (77 mg,0.28mmol,1.1 eq.) was added and the mixture stirred at room temperature overnight, then extracted with DCM and water, washed with NaCl brine and concentrated in vacuo to give the crude product. The crude product was purified by flash chromatography on silica gel (DCM: meoh=20:1) and the pure fractions were concentrated in vacuo to give LL-K9-018 as a white solid (156 mg, 66%). HRMS [ M+H ]] + C 40 H 66 N 9 O 11 S 3 + Calculated as 944.4044, found 944.4125. 1 H NMR(400MHz,CD 3 OD)δ7.32(s,1H),6.68(s,1H),4.04–4.00(m,1H),3.99(s,2H),3.83–3.78(m,2H),3.37(t,J=6.4Hz,2H),3.21(t,J=6.7Hz,2H),2.98–2.90(m,2H),2.66–2.59(m,1H),1.97–1.91(m,2H),1.88–1.73(m,4H),1.68–1.59(m,4H),1.52(s,9H),1.47(s,9H),1.45(s,9H),1.24(s,9H).
Example 20: preparation of Compound LL-K9-019
Step 1:
1-adamantanecarboxylic acid (0.5 g,2.8 mmol) was dissolved in DMF (10 mL), EDCI (1.07 g,5.5 mmol), HOBt (0.375 g,2.8 mmol), glycine methyl ester hydrochloride (0.35 g,22.8 mmol) was added followed by triethylamine (1.24)mL,8.9 mmol). The mixture was stirred at room temperature for 3 hours, and the reaction was quenched with water (50 mL). The aqueous phase was extracted with EA (2X 150 mL), the combined organic phases were washed with water (2X 80 mL), saturated NaCl brine (50 mL), and dried (Na 2 SO 4 ) Concentrating in vacuum. A white solid (0.59 g, 84%) was obtained and used in the next step without further purification.
Step 2:
1- ((3 r,5r,7 r) -adamantyl-1-carbonyl) -glycine methyl ester (0.59 g,2.3 mmol) was dissolved in methanol (10 mL), sodium hydroxide (188 mg,4.6 mmol) was dissolved in water (1 mL), and aqueous sodium hydroxide solution was added to a methanol solution of 1- ((3 r,5r,7 r) -adamantyl-1-carbonyl) -glycine methyl ester. The mixture was reacted at 70℃for 2 hours, after which time the system was cooled to room temperature and water (100 mL) was added. The aqueous phase was adjusted to ph=1 with dilute hydrochloric acid (6M) and extracted with EA (2×70 mL), dried (Na 2 SO 4 ) Concentrated in vacuo to give a white solid (0.4 g, 71%) which was used in the next step without further purification.
Step 3:
/>
1- ((3 r,5r,7 r) -adamantyl-1-carbonyl) -glycine (59.25 mg,0.25mmol,1 eq.) HATU (68.5 mg,0.18mmol,1.2 eq.) and DIPEA (105. Mu.L, 0.6mmol,4 eq.) were dissolved in DMF (2 mL), the mixture stirred for 10 min, then SNS-032 (57 mg,0.15mmol,1 eq.) was added. The mixture was stirred at room temperature overnight and extracted with DCM and water. The organic phase was separated, washed with NaCl brine and concentrated in vacuo to give a crude product as a solid. The crude product was purified by flash chromatography on silica gel (DCM: meoh=20:1) and the pure fractions were concentrated to give LL-K9-019 (58.40 mg, 65%) as a white solid. 1 H NMR(600MHz,Chloroform-D)δ7.26(s,1H),6.89(t,J=3.9Hz,1H),6.56(s,1H),4.47(dd,J=9.7,3.6Hz,1H),4.06(qd,J=17.5,3.9Hz,2H),3.94(s,2H),3.84–3.78(m,1H),3.14–3.09(m,1H),2.94–2.87(m,1H),2.76–2.70(m,1H),2.02(s,3H),1.95–1.89(m,2H),1.86(d,J=2.4Hz,6H),1.80(ddd,J=23.9,14.3,3.9Hz,2H),1.69(dd,J=31.1,11.9Hz,6H),1.23(s,9H)。
Example 21: preparation of Compound LL-K9-020
Step 1:
1-adamantanecarboxylic acid (25 g,138 mmol) was dissolved in methanol (150 mL), concentrated sulfuric acid (4 mL) was added with stirring, and the mixture was refluxed at 80℃for 3 hours. The organic phase was concentrated in vacuo, the remaining oil diluted with water (250 mL), extracted with EA (2X 250 mL), the organic phase washed with water (2X 150 mL), naCl brine (100 mL), and dried (Na) 2 SO 4 ) Concentrated in vacuo and the crude product was passed on a silica gel column (mobile phase 2% (EA: PE)) to give methyl 1-adamantane carboxylate as a white solid (21.8 g, 81%). 1 H NMR(600MHz,Chloroform-D)δ3.61(s,3H),1.97(s,3H),1.85(d,J=2.7Hz,6H),1.67(q,J=12.2Hz,6H).
Step 2:
lithium Aluminum Hydride (LAH) (6.41 g,168 mmol) was suspended in THF (250 mL) under nitrogen and cooled to 0deg.C. Methyl 1-adamantanecarboxylate (21.8 g,112 mmol) was dissolved in THF (50 mL), and the reaction solution was slowly dropped at 0 ℃. After the completion of the dropwise addition, the mixture was stirred at room temperature for 1 hour, and then EA (100 mL) and water (20 mL) were added dropwise at 0 ℃. All liquids were filtered through celite, the solvent was removed in vacuo, and dried (Na 2 SO 4 ) A colorless oil (17 g, 91%) was obtained. 1 H NMR(600MHz,Chloroform-D)δ3.17(s,2H),1.96(s,3H),1.73–1.60(m,6H),1.48(d,J=2.5Hz,6H).
Step 3:
chromium chloridePyridine (PCC) (23.17 g,107.5 mmol) was suspended in DCM (150 mL) and DCM (100 mL) dissolved in 1-adamantanemethanol (10.5 g,63.2 mmol) was added with stirring at room temperature. After 1 hour, it was diluted with diisopropyl ether (750 mL) and filtered through celite. The filtrate was washed with 1N NaOH (250 mL), water (2X 150 mL), and the organic phase was dried (Na 2 SO 4 ) White solid (8.94 g, 86%) was obtained. 1 H NMR(600MHz,Chloroform-D)δ9.30(s,1H),2.05(s,3H),1.76(d,J=12.4Hz,3H),1.72–1.66(m,9H)。
Step 4:
SNS-032 (57 mg,0.15mmol,1 eq.) was dissolved in DCM (2 mL), triethylamine (41.6. Mu.L, 0.3mmol,2 eq.) and the compound adamantane-formaldehyde (61.5 mg,0.375mmol,2.5 eq.) were added and the mixture stirred for 45min before sodium triacetoxyborohydride (32.0 mg,0.3mmol,2 eq.) was added. The mixture was stirred at room temperature overnight, then extracted with DCM and water, the organic phase separated, washed with NaCl brine and concentrated in vacuo to give the crude product. The crude product was purified by flash chromatography on silica gel (DCM: meoh=20:1) to give LL-K9-020 (41.2 mg, 52%) as a white solid. 1 H NMR(600MHz,Chloroform-D)δ7.30(s,1H),6.59(s,1H),3.95(s,2H),2.82(d,J=11.1Hz,2H),2.31(d,J=11.4Hz,1H),2.26(t,J=10.9Hz,2H),1.90(dd,J=29.9,9.4Hz,5H),1.79–1.66(m,7H),1.62(d,J=11.7Hz,3H),1.47(s,6H),1.24(s,9H)。
Example 22: preparation of Compound LL-K9-021
Step 1:
sodium hydride (2.38 g,99 mmol) was suspended in THF (200 mL), trimethyl phosphorylacetate (TMPA) (12.89 g,70.8 mmol) was slowly added at 0deg.C, stirred for 15 min, then 1-adamantane-formaldehyde in THF was added dropwise at 0deg.C, stirred for 1.5 h at 5deg.C, quenched with water (50 mL), and THF was removed in vacuo. The mixture was added with water (150 mL) and extracted with EA (2X 150 mL). The organic phase was desolventized in vacuo and dried to give a white solid mixture (10.75 g, 91%) which was used in the next step without further purification.
Step 2:
methyl 1-adamantyl propionate (12.75 g,57.9 mmol) was dissolved in methanol (150 mL), sodium hydroxide (6.95 g,173 mmol) was dissolved in water (10 mL), sodium hydroxide solution was added to the methyl 1-adamantyl propionate in methanol, and after stirring at 70℃for 2 hours, the mixture was desolvated in vacuo, water (150 mL) was added, and extracted with EA (150 mL). The organic phase was adjusted to ph=2 with hydrochloric acid and then cooled to 5 ℃ for 30 minutes, and the precipitate was filtered and dried in vacuo to give a white solid (7.4 g, 62%). 1 H NMR(600MHz,Chloroform-D)δ6.92(d,J=15.9Hz,1H),5.67(d,J=15.9Hz,1H),2.02(s,3H),1.75(d,J=12.3Hz,3H),1.66(d,J=11.3Hz,3H),1.63(d,J=2.5Hz,6H)。
Step 3:
1-adamantyl-allylic acid (7.4 g,33.9 mmol) was dissolved in 200mL of methanol, and 10% Pd/C (10%, 1.48 g) was added. The mixture was bubbled with nitrogen for 15 minutes, and then reacted at room temperature under a hydrogen atmosphere for 1 day. The reaction mixture was filtered through celite and the solvent was removed in vacuo to give a white solid (7.31 g, 97%) which was used in the next step without further purification.
Step 4:
1-adamantylpropionic acid (31 mg,0.25mmol,1 eq.) HATU (68.5 mg,0.18mmol,1.2 eq.) and DIPEA (105. Mu.L, 0.6mmol,4 eq.) were dissolved in DMF (2 mL), the mixture was stirred for 10 min, then SNS-032 @ was added57mg,0.15mmol,1 eq). The mixture was stirred at room temperature overnight and extracted with DCM and water. The organic phase was separated, washed with NaCl brine and concentrated in vacuo to give a crude product as a solid. The crude product was purified by flash chromatography on silica gel (DCM: meoh=20:1) and the purified fractions were concentrated to give LL-K9-021 (50.44 mg, 59%) as a white solid. 1 H NMR(600MHz,Chloroform-D)δ7.26(s,1H),6.55(s,1H),4.53(d,J=13.3Hz,1H),3.93(s,2H),3.90(d,J=13.6Hz,1H),3.12(d,J=11.0Hz,1H),2.74(dd,J=18.2,6.9Hz,1H),2.67(ddd,J=14.6,10.7,3.7Hz,1H),2.30–2.25(m,2H),1.95–1.86(m,5H),1.84–1.77(m,1H),1.69(dd,J=28.0,11.7Hz,4H),1.58(d,J=11.7Hz,3H),1.44(s,6H),1.40(d,J=7.5Hz,2H),1.21(s,9H)。
Example 23: preparation of Compound LL-K9-022
Step 1:
1-adamantylpropionic acid (7.2 g,34.6 mmol) was added to 150mL of methanol with stirring, concentrated sulfuric acid (2 mL) was added, the mixture was reacted at 80℃for 3 hours, the reaction was desolventized in vacuo, the residue was diluted with water (250 mL), extracted with EA (2X 250 mL), the organic phase was washed with saturated NaCl brine (1X 100 mL), and dried (Na) 2 SO 4 ) The solvent was removed in vacuo to give a white solid (7.34 g, 95%) which was used in the next step without further purification.
Step 2:
lithium aluminum hydride (LAH, 2.51g,66 mmol) was dissolved in THF (100 mL), a solution of 1-adamantyl methyl propionate (7.34 g,33 mmol) in THF (50 mL) was added dropwise at 0deg.C, and after stirring the mixture at room temperature for 1 hour, the reaction solution was cooled to 0deg.C again, and EA (20 mL) and water (5 mL) were added dropwise slowly. The mixture was filtered through celite, dried (Na 2 SO 4 ) Concentrating in vacuum. The crude product was passed through a silica gel column (EA: pe=5%) to give an oil (5.2 g, 81%) which was purified without further purificationFor the next step.
Step 3:
PCC (7.55 g,36 mmol) was suspended in DCM (50 mL) and DCM (50 mL) dissolved in 1-adamantylpropanol (3.5 g,18 mmol) was added. After the mixture was stirred at room temperature for 1 hour, diisopropyl ether (150 mL) was added and filtered through celite. Then washed with 1N sodium hydroxide (2X 100 mL) and water (2X 100 mL), dried (Na 2 SO 4 ) Concentrated in vacuo to give a white oil (3.13 g, 90%) which was used in the next step without further purification.
Step 4:
/>
SNS-032 (57 mg,0.15mmol,1 eq.) was dissolved in DCM (2 mL), triethylamine (41.6. Mu.L, 0.3mmol,2 eq.) and the compound adamantane propionaldehyde (72.0 mg,0.375mmol,2.5 eq.) were added and the mixture stirred for 45min, then sodium triacetoxyborohydride (32 mg,0.3mmol,2 eq.) was added. The mixture was stirred at room temperature overnight, then extracted with DCM and water, the organic phase separated, washed with NaCl brine and concentrated in vacuo to give the crude product. The crude product was purified by flash chromatography on silica gel (DCM: meoh=20:1) to give LL-K9-022 as a white solid (37.6 mg, 45%). 1 H NMR(600MHz,Chloroform-D)δ7.31(s,1H),6.58(s,1H),3.95(s,2H),3.06(d,J=11.5Hz,2H),2.46(d,J=6.4Hz,1H),2.41–2.33(m,2H),2.15(s,2H),1.93(d,J=20.3Hz,7H),1.67(d,J=11.9Hz,3H),1.59(d,J=11.6Hz,3H),1.49(dd,J=13.0,8.2Hz,2H),1.44(s,6H),1.23(s,9H),1.03–0.98(m,2H)。
Example 24: preparation of Compound LL-K9-023
Step 1:
1-adamantaneacetic acid (2.00 g,10.3mmol,1 eq.) was dissolved in THF (34 mL) under nitrogen, cooled to 0deg.C, and LAH (1M solution in THF, 15.5mL,15.4mmol,1.5 eq.) was slowly added dropwise. After the completion of the dropwise addition, the reaction mixture was warmed to room temperature and reacted for 18 hours. After 0℃water (50 mL) was added and quenched, the mixture was extracted with EA (2X 50 mL). The organic phases were combined, washed with 3N hydrochloric acid (20 mL), saturated NaCl brine, dried (Na 2 SO 4 ) Concentrated in vacuo to give a colorless oil (1.78 g, 96%). 1 H NMR(600MHz,Chloroform-D)δ3.72–3.68(m,2H),1.93(s,3H),1.69(d,J=12.1Hz,3H),1.65–1.59(m,3H),1.51(d,J=2.2Hz,6H),1.40–1.35(m,2H)。
Step 2:
oxalyl chloride (1 mL,11.7mmol,2 eq.) was dissolved in DCM (80 mL) and cooled to-78deg.C. DMSO (1.65 mL,23.3mmol,2.4 eq.) was added dropwise, followed by stirring for 15 min and 1-adamantaneethanol (1.75 g,9.71mmol,1 eq.) was added dropwise to DCM (17 mL). After the completion of the dropwise addition, stirring was carried out at the same temperature for 30 minutes. Triethylamine (8.2 mL,58.2mmol,6 eq) was slowly added dropwise over 20 min after the reaction, then the reaction was slowly warmed to room temperature and stirred at room temperature for 40 min, saturated sodium bicarbonate (50 mL) was added and stirred for 30 min before extraction with DCM (3×50 mL). The combined organic phases were washed with water (50 mL), saturated NaCl brine (50 mL), dried (Na 2 SO 4 ) Concentrating in vacuum. Column over silica gel (EA: pe=5%). A colorless oil (1.43 g,8.02mmol, 83%) was obtained. 1 H NMR(600MHz,Chloroform-D)δ9.87(t,J=3.3Hz,1H),2.12(d,J=3.3Hz,2H),1.98(s,3H),1.72(d,J=12.1Hz,3H),1.65(dd,J=13.4,2.0Hz,9H)。
Step 3:
SNS-032 (57 mg,0.15mmol,1 eq.) was dissolved in DCM (2 mL) and triethylamine (41.6. Mu.L, 0.3mmol,2 eq.) and the compound adamantane acetaldehyde (66)75mg,0.375mmol,2.5 eq.) and the mixture stirred for 45min, then sodium triacetoxyborohydride (32 mg,0.3mmol,2 eq.) was added. The mixture was stirred at room temperature overnight. The organic phase was then separated by extraction with DCM and water, washed with NaCl brine and concentrated in vacuo to give the crude product. The crude product was purified by flash chromatography on silica gel (DCM: meoh=20:1) to give LL-K9-023 (36.5 mg, 60%) as a white solid. 1 H NMR(600MHz,Chloroform-D)δ7.32(s,1H),6.58(s,1H),3.95(s,2H),3.03(d,J=11.5Hz,2H),2.42(d,J=5.2Hz,1H),2.40–2.35(m,2H),2.05(t,J=14.7Hz,2H),1.91(s,7H),1.67(t,J=8.9Hz,3H),1.60(d,J=11.5Hz,3H),1.47(d,J=2.1Hz,6H),1.31–1.27(m,2H),1.22(s,9H)。
Example 25: preparation of Compound LL-K9-024
Step 1:
3, 3-triphenylacetic acid (2.88 g,10mmol,1 eq.) HATU (4.56 g,12mmol,1.2 eq.) and DIPEA (6.95 mL,40mmol,4 eq.) were dissolved in DMF (20 mL), the mixture stirred for 10 min, then 2, 2-diethoxyethyl-1-amine (1.33 g,10mmol,1 eq.) was added. The mixture was stirred at room temperature overnight and then extracted with EA and water. The organic phase was separated, washed with NaCl brine and concentrated in vacuo to give a crude product as a solid. The crude product was purified by flash chromatography on silica gel (PE: ea=2:1) and concentrated in vacuo to give N- (2, 2-diethoxyethyl) -2, 2-triphenylacetamide as a white solid (2.86 g, 71%). 1 H NMR(400MHz,CDCl 3 )δ7.30–7.22(m,15H),6.06(s,1H),4.46(t,J=5.5Hz,1H),3.62(dq,J=9.3,7.1Hz,2H),3.48–3.39(m,4H),1.11(t,J=7.0Hz,6H)。
Step 2:
n- (2, 2-Diethoxyethyl) -2, 2-triphenylacetamide (302 mg,0.75mmol,1 eq.) was dissolved in MeCN (1 mL), addedHCl (1N, 1 mL) was added, the mixture was stirred at room temperature overnight, extracted with DCM and water, the post organic phase washed with water, saturated NaCl brine, na 2 SO 4 Dried, concentrated in vacuo, and N- (2-oxyethyl) -2, 2-triphenylacetamide was used in the next step without further purification.
Step 3:
SNS-032 (57 mg,0.15mmol,1 eq.) was dissolved in DCM (2 mL), triethylamine (41.6. Mu.L, 0.3mmol,2 eq.) and the compound N- (2, 2-diethoxyethyl) -2, 2-triphenylacetamide (123.0 mg,0.375mmol,2.5 eq.) were added and the mixture stirred for 45min, followed by sodium triacetoxyborohydride (32 mg,0.3mmol,2 eq.). The mixture was stirred at room temperature overnight. The organic phase was then separated by extraction with DCM and water, washed with NaCl brine and concentrated in vacuo to give the crude product. The crude product was purified by flash chromatography on silica gel (DCM: meoh=20:1) to give LL-K9-024 (35.4 mg, 34%) as a white solid. 1 H NMR(600MHz,Chloroform-D)δ7.30–7.25(m,15H),6.58(s,1H),6.53(t,J=4.4Hz,1H),3.95(s,2H),3.42(d,J=5.2Hz,2H),2.73(d,J=11.2Hz,2H),2.41(s,2H),2.27(t,J=10.7Hz,1H),1.92(s,2H),1.70(d,J=11.5Hz,2H),1.60–1.52(m,2H),1.24(s,9H)。
Example 26: preparation of Compound LL-K9-025
Step 1:
to 3, 3-triphenylpropionic acid (3.02 g,10mmol,1 eq.) HATU (4.56 g,12mmol,1.2 eq.) and DIPEA (6.95 mL,40mmol,4 eq.) were dissolved in DMF (20 mL), the mixture was stirred for 10 min, then 2, 2-diethoxyethyl-1-amine (1.33 g,10mmol,1 eq.) was added and the mixture stirred at room temperature overnight, then extracted with EA and water. The organic phase was separated, washed with NaCl brine and concentrated in vacuo to give a crude product as a solid. By rapid silica gelThe crude product was purified by chromatography (PE: ea=2:1) and concentrated in vacuo to give N- (2, 2-diethoxyethyl) -3, 3-triphenylpropionamide as a white solid (3.54 g, 85%). 1 H NMR(400MHz,CDCl 3 )δ7.31–7.27(m,12H),7.24–7.18(m,3H),5.12(s,1H),4.12(t,J=5.4Hz,1H),3.58(s,2H),3.55–3.47(m,2H),3.41–3.29(m,2H),3.07(t,J=5.6Hz,2H),1.11(t,J=7.0Hz,6H)。
Step 2:
n- (2, 2-Diethoxyethyl) -2, 2-triphenylacetamide (312 mg,0.75mmol,1 eq.) was dissolved in MeCN (1 mL), HCl (1N, 1 mL) was added, the mixture was stirred at room temperature overnight, extracted with DCM and water, and the organic phase was washed with water, saturated NaCl brine, na 2 SO 4 Drying and vacuum concentration to obtain N- (2-oxyethyl) -3, 4-triphenyl propionamide, which can be used for the next step without further purification.
Step 3:
SNS-032 (57 mg,0.15mmol,1 eq.) was dissolved in DCM (2 mL), triethylamine (41.6. Mu.L, 0.3mmol,2 eq.) and the compound N- (2-oxyethyl) -3, 3-triphenylpropionamide (257.0 mg,0.375mmol,2.5 eq.) were added and the mixture stirred for 45min, then sodium triacetoxyborohydride (32.0 mg,0.3mmol,2 eq.) was added. The mixture was stirred at room temperature overnight, then extracted with DCM and water, the organic phase separated, washed with NaCl brine and concentrated in vacuo to give the crude product. The crude product was purified by flash chromatography on silica gel (DCM: meoh=20:1) followed by semi-preparative HPLC (flow rate, 10mL/min; solvent a MeOH: mecn=1:1; solvent B is 0.1% tfa in water; gradient: eluting from 5% a to 95% a over 30min, 30-45min 95% a) to give LL-K9-025 (17 mg, 16%) as a white solid. 1 H NMR(600MHz,Chloroform-D)δ7.29–7.21(m,15H),7.09(s,1H),6.62(s,1H),3.99(s,2H),3.59(s,2H),3.30-3.48(m,4H),2.94-3.03(m,1H),2.84(s,2H),2.63-2.71(m,1H),2.28–2.04(m,1H),1.27(s,9H)。
EXAMPLE 27 determination of the Activity of the Compounds of the invention to degrade CDK9-cyclin T1 Complex
The ability of each of the compounds in the above examples to degrade CDK9-cyclin T1 in vitro was measured and the cell line selected as prostate cancer cell 22RV1 was as follows: cells were cultured using RPMI1640 medium (Gibco, available from Life Technologies, 22400-089) to which 10% fetal bovine serum (Gibco, available from Life Technologies, 10099-141) and 1% antibiotics (penicillin and streptomycin, available from Life Technologies, 10378016) were added. Before testing, cells in logarithmic growth phase were selected at 5X 10 5 Individual cells/well were seeded in 12-well plates. After 24 hours, the compounds of each example were diluted to 3. Mu.M, 1. Mu.M and 0.3. Mu.M with medium, and the medium for each well of cells was changed to medium liquid containing the compound of the example at the above concentration. After 24 hours of treatment, the medium was discarded, and the cells were washed with pre-chilled PBS, and after the liquid was removed, SDS cell lysis buffer was added, and the cells were lysed by leaving on ice for 15 minutes, and then the sample was heated on a 99℃metal bath heater for 10 minutes. Lysates were separated by SDS-PAGE gel electrophoresis, total protein was transferred to NC membrane, and after blocking with TBST buffer containing 5% skim milk for one hour, target protein was identified using antibodies against CDK9 (Cell Signaling Technology, cat# 2316) and against cyclin T1 (Abcam, cat# ab 184703), and internal reference GAPDH was identified using antibodies against GAPDH (Cell Signaling Technology, cat# 5174). After the above primary antibodies were incubated overnight with the membrane, the membrane was washed with TBST buffer, and the remaining primary antibodies were washed off, and incubated on a shaker for 10 minutes each time, 3 times in total. After 1 hour incubation with the secondary antibody with the membrane, the membrane was washed with TBST buffer and the remaining primary antibody was washed off, and incubated on a shaker for 10 minutes each time for a total of 3 washes. The developer was SuperSignal WestDura (available from Thermo Scientific, cat# 34076) and the developer was GE ImageQuant LAS 4000 systems. The specific degradation activity of the above compounds is shown in FIG. 1.
The result shows that the compound disclosed by the invention can degrade CDK9 and cyclin T1 proteins, and the compound disclosed by the invention can realize the degradation of CDK9-cyclin T1 complex, especially LL-K9-015 in the compound, and has strong degradation activity. The degradation activity of compound LL-K9-015 on CDK9 and cyclin T1 in the concentration range of 12. Mu.M-0. Mu.M (2-fold dilution, initial concentration 12. Mu.M, 9 concentration points) was further analyzed and Western immunoblots were analyzed for gray scale using ImageJ, graphPad Prism9 fitted with a concentration-relative protein abundance curve to give LL-K9-015 DCs for CDK9 and cyclin T1 50 0.662 μm and 0.589 μm, respectively (fig. 2).
Example 28 determination of degradation kinetics
The kinetics of degradation of compound LL-K9-015 in 22RV1 cells was determined in this example using DIA-MS based proteomics and Western immunoblotting.
Proteomics method based on DIA-MS the procedure for determining the degradation kinetics of LL-K9-015 is as follows: 22RV1 cells were used in 1.2X10 manner 6 A density of/ml was applied to a 6-well plate. After cell attachment, LL-K9-015 was diluted to a final concentration of 3. Mu.M in culture medium, SNS032 was used as control inhibitor, and also to 3. Mu.M in culture medium containing DMSO at the same concentration as a blank. The compound groups were dosed simultaneously, each group being set for 5 incubation times, 3 hours, 9 hours, 12 hours, 24 hours, 36 hours, respectively. Three duplicate samples were set for each group. After reaching the incubation time, each group of samples was washed 3 times with pre-chilled PBS buffer, 200. Mu.L of cell lysate (4% SDS,100mM Tris-HCl, pH 7.6,0.1M DTT) was added, and the cells were scraped off with a disposable cell scraper and placed in the EP tube. Heating at 100deg.C for 10 min, then sonicating for 30s, collecting supernatant, determining protein concentration by tryptophan method, and performing quality detection on cell sample by SDS-PAGE electrophoresis. And (5) after the quality is qualified, performing enzymolysis by using a FASP method. Desalting the obtained peptide fragment with C18 membrane, lyophilizing, and storing in-80deg.C refrigerator. Dissolving the dried peptide sample with 0.1% formic acid water, quantifying nanodrop, taking 1ug peptide, and separating by EASY-nLC 1000 nano-flow ultra-high performance liquid chromatography with flow rate of 300nl min-1. The column was a self-contained nanofiltration C18 column (3 um,120a,75um x 15 cm). Mobile phase A was 0.1% Formic acid-water solution, mobile phase B was 0.1% formic acid-acetonitrile solution. The analysis gradient is 0-72 min,3% -27% B; 72-82 min, 27-35% B; 82-84 min, 35-100% B;84-90min,100% B. The sample was separated by liquid chromatography and mass spectrometry was performed using a Q exact HF mass spectrometer. The Full MS-DIA method has the primary resolution of 120K, the scanning range of 350-1500 m/z, the AGC of 3e6 and the maximum ion implantation time of 100MS. The fragmentation energy of the parent ion was 27%. The resolution of the secondary scan was 30K, AGC to 5e5 and the maximum ion implantation time was 50ms. The obtained data refers to Uniprot human protein database, DIA original data is searched by using DIA-NN1.7.16 software built-in parameters. The GraphPad Prism 9.3 draws a degradation curve of key proteins, and the result shows that the compound LL-K9-015 can realize synchronous degradation of CDK9 and cyclin T1, while the prototype compound SNS032 does not have the capacity of degrading CDK9 and cyclin T1 (figure 3).
The procedure for determining the degradation kinetics of LL-K9-015 based on Western blotting was as follows: 22RV1 cells were used in an amount of 0.5X10 6 The density of individual cells/wells was plated on 12-well plates, after which cells were attached, the cells were treated with medium containing 3. Mu.M LL-K9-015 for 0, 1, 3, 5, 7, 9, 11, 16, 24, 36, 48 hours, lysed with SDS, and denatured at 99℃for 10 minutes. A western blot experiment was then performed to detect the abundance of the target protein. The results show that the compound LL-K9-015 can realize the synchronous degradation of CDK9 and cyclin T1, the degradation of CDK9 and cyclin T1 begins to occur in 9-11 hours, and two proteins are significantly degraded in 24 hours. This suggests that LL-K9-015 induced degradation of CDK9-cyclin T1 complex (FIG. 4).
EXAMPLE 29 evaluation of degradation Selectivity within the CDK, cyclin family
In this example, human prostate cancer cells 22RV1 were measured at a ratio of 0.5X10 6 The density of individual cells/wells was plated on 12-well plates, after cell attachment, the cell growth medium was changed to that containing 6. Mu.M-0.38. Mu.M LL-K9-015, treated for 24 hours, lysed with SDS, and denatured at 99℃for 10 minutes. Western blot experiments were then performed to detect the abundance of CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK9, cyclin E1, cyclin T1, cyclin H, and cyclin T2. ExperimentThe results indicate that LL-K9-015 selectively degrades CDK9-cyclin T1 complex without significant effect on the remaining CDK family of proteins. Although prototype compound SNS032 also inhibited CDK2 and CDK7, LL-K9-015 had only a weak down-regulation of the regulatory subunit cyclin E1 of CDK2 at high concentrations, no significant effect on the regulatory subunit cyclin H of CDK7, and only a partial degradation of the minor binding subunit cyclin T2 of CDK9 at high concentrations (fig. 5A-5B).
Example 30 proteome evaluation of degradation selectivity
This example evaluates the effect of LL-K9-015 on whole proteome according to the method of the proteome of DIA-MS in example 28. In example 28, the CDK9-cyclin T1 complex was significantly degraded 24 hours after treatment of the cells with LL-K9-015, and 24 hours was chosen as the time point for analysis of proteome selectivity. The LL-K9-015 and SNS032 group differential expression proteins are screened by using R4.1.1 according to the standard that the fold change is more than or equal to 1.5 or 0.67 and the P-value is less than or equal to 0.05. Volcanic plot shows that SNS032 has slight up-regulation effect on cyclin T1, significant down-regulation effect on cyclin D1, and no effect on the rest CDK and cyclin proteins; LL-K9-015 significantly down-regulates CDK9 and cyclin T1. Since CDK9 regulates transcription of cycle-associated cyclin proteins, cycle-associated cyclin A2, cyclin B1 and cyclin D1 are also significantly down-regulated. Other binding targets for the prototype compound SNS032 of LL-K9-015 were not identified as differential proteins, indicating selective degradation of CDK9-cyclin T1 complex by LL-K9-015 (FIGS. 5C-5D).
Example 31 determination of in vitro anti-tumor Activity of some Compounds
In this example, the inhibitory activity of a compound against cell proliferation was examined using human prostate cancer cell line 22RV1 cells as a model. When the cells are in exponential growth phase, the cells are harvested, counted and inoculated. In 96-well plates, 100 μM cells per well was made 5000 cells per well, and a blank was added with 100 μM complete medium; compound treatment was given simultaneously, with a concentration gradient of 100 μm as starting concentration, three-fold gradient dilution, 9 concentration points total. The change in cell proliferation after 5 days of administration was detected by CellTiter-Glo method (Promega, G7572). The checking method comprises the following steps: the prepared CellTiter-Glo was added to 100. Mu.M to 96 well plates and the cell plates were placedShaking on a shaking table for 10min, and standing at normal temperature for 5min. The treated cells were transferred to a white 384 well plate (OptiPlate-384, available from Perkinelmer, inc. 6007299) at 60. Mu.L/well and cold-luminescence signals were detected at 400-700 nm using a multifunctional microplate reader EnVision (available from Perkinelmer, inc.). Analysis of data using GraphPad Prism 9.3 software, mapping of cell viability on ordinate and drug concentration on cross-arm, and calculation of IC for inhibition of proliferation of each cell line by the compound 50 。
The cell viability (%) was calculated as:
survival (%) = (dosing well OD-blank well OD)/(control well OD-blank well OD) ×100%
Table 1 partial example compounds antiproliferative activity data on prostate cancer cells 22RV1
Compounds of formula (I) | IC 50 (μM) |
LL-K9-003 | 0.068 |
LL-K9-016 | 0.255 |
LL-K9-017 | 0.564 |
LL-K9-015 | 0.120 |
LL-K9-023 | 0.236 |
LL-K9-024 | 0.350 |
SNS032 (prototype Compound control) | 0.384 |
The in vitro antiproliferative activity of the compounds with superior degradation activity is shown in Table 1, which shows that several compounds have stronger antiproliferative activity, especially LL-K9-015 and LL-K9-003, compared to the prototype compound SNS 032. Therefore, the compound can be used for preparing anticancer drugs. The compound provided by the invention has remarkable capability of degrading CDK9-cyclin T1 complex, and can be used in medicines for treating diseases related to CDK9-cyclin T1, especially in treatment of tumors, because CDK9-cyclin T1 complex has a critical role in tumor cell growth and proliferation.
EXAMPLE 32 cloning experiments
In this example, human prostate cancer cell line 22RV1 cells in logarithmic growth phase were inoculated into 12-well transparent cell culture plates at 800 cells/well, after 24 hours, the medium per well was changed to medium containing 400nM, 200nM, 100nM of LL-K9-015 or SNS032 of the same concentration, and the culture was continued with medium containing 0.1% (v/v) DMSO as a control for 14 days, during which the medium containing the corresponding compound or 0.1% (v/v) DMSO was changed to freshly prepared medium containing the compound or DMSO every 2 days. After 14 days of incubation, the medium was discarded, the cells were washed twice with PBS buffer, fixed with 4% paraformaldehyde for 10 min, washed twice with PBS, then stained with crystal violet staining solution (Biyundian, cat# C0121) for 20 min, washed with PBS to remove excess staining solution, dried at room temperature, and photographed. The results indicate that LL-K9-015 dose-dependently inhibited 22RV1 cell clonogenic and was significantly stronger than SNS032 (FIG. 6B). This indicates that the degradation of CDK9-cyclin T1 has a stronger ability to inhibit tumor cell proliferation.
Example 33 cell cycle and apoptosis experiments
In this example, human prostate cancer cell line 22RV1 cells in logarithmic growth phase were cultured in a 6X 10 manner 5 After 24 hours of seeding of the cells/well into 6-well transparent cell culture plates, 1. Mu.M or 0.3. Mu.M compound was added and incubation was continued in a cell incubator at 37℃with 5% CO2 for 24 hours, with 0.1% (v/v) DMSO as a control. Cells were collected by centrifugation at 1000rpm and washed once with PBS to remove the medium. Cells were finally resuspended in pre-chilled PBS containing 70% (v/v) ethanol and fixed overnight at 4 ℃. The ethanol was removed by centrifugation and resuspended after one wash with FACS buffer. Finally, RNase and Propidium Iodide (PI) were added at the recommended concentrations (BD Pharmingen), stained at room temperature for 20min, and examined on a flow cytometer (BioRad ZE 5). Propidium Iodide dye can be combined with RNA and DNA, and DNA can be detected only by degrading RNA with RNase, the number of DNA in G1 phase of a cell is half of that in G2 phase, and the number of DNA in S phase is between the two, so that the cycle state of the cell can be judged by detecting the fluorescent signal value of the dye.
In this example, the effect of compounds LL-K9-015 and SNS032 on apoptosis of 22RV1 was examined by apoptosis experiments, by first dividing 22RV1 cells by 6X 10 5 Individual cell densities were seeded in 12-well plates (Corning). After 24 hours of compound treatment, cell samples were collected. Samples were then treated with an Annexin V-FITC apoptosis detection kit (nanking biosciences, a 211-01) and the apoptotic state was detected with a BioRad ZE5 flow meter, and data analysis was done using Modfit and FlowJo software (version 7.6.1). The results showed that after 24 hours of treatment with LL-K9-015 and SNS032, a portion of 22RV1 cells were arrested in the G1/S phase and a portion of cells were arrested in the sub-G1 phase (apoptotic phase), with LL-K9-015 having a greater arrest capacity. Meanwhile, detection of apoptosis levels by flow cytometry showed that LL-K9-015 caused more apoptosis than SNS032 (FIG. 7).
EXAMPLE 34 Western blot experiments of CDK 9-associated pathway and target protein proteins
In this example, human prostate cancer cells 22RV1 were measured at a ratio of 0.5X10 6 The density of individual cells/well was spread on a 12-well plate, and after the cells had adhered to the wall, the cell growth medium was changed to contain 3. Mu.M, 1. Mu.M, 0.3mu.M of LL-K9-015 or SNS032 medium, treated for 24 hours, lysed with SDS and denatured at 99℃for 10 minutes. Western blot experiments were then performed to detect the abundance of MCL1, cMyc, AR, ARv, KLK3, NKX3-1, phospho-Rpb1 CTD (Ser 5), phospho-Rpb1 CTD (Ser 2), and RNA pol II antibody. Experimental results show that LL-K9-015 significantly inhibited RNA pol II phosphorylation, significantly down-regulated protein levels of MCL1, cMyc, AR, ARv7, KLK3, NKX3-1, and inhibited more completely than SNS032 (FIG. 8).
Example 35: transcriptome analysis
In this example, prostate cancer cells 22RV1 were treated with 2. Mu.M LL-K9-015, 2. Mu.M Thal-SNS032, 2. Mu.M MSNS032 and 0.1% DMSO for 24 hours, and cell samples were collected and were phenol/chloroform extracted for total RNA, purity was checked by NanoDrop 2000&8000 micro-spectrophotometry, concentration was determined by Agilent 2100Bioanalyzer, and integrity was checked by Agilent RNA 6000Nano Kit. Only samples that passed the purity and integrity tests were subjected to the next library analysis. The pooled samples were high-throughput sequenced by Illumina NovaSeq 6000, sequencing read length PE150. The washed data were aligned by STAR software and the reference genome was UCSC hg19. And submitting the compared bam file to the featuresource software for quantitative analysis. Differential gene analysis was performed by R package Deseq2, with differential gene threshold of logFC >1.5, corrected p value less than 0.05. The clustering analysis is completed by R packets Clusterfile, the p value of the clustering is corrected by adopting an FDR method, and the threshold value of the significance is that the corrected p value is smaller than 0.05. The results indicate that the changes in the transcriptome caused by LL-K9-015 are significantly different from those caused by SNS032 and Thal-SNS032, and that LL-K9-015 inhibits MYC and AR mediated oncogenes and down regulates MYC and AR target genes (FIG. 9).
All documents mentioned in this application are incorporated by reference as if each were individually incorporated by reference. Further, it will be appreciated that various changes and modifications may be made by those skilled in the art after reading the above teachings, and such equivalents are intended to fall within the scope of the claims appended hereto.
Claims (10)
1. An oxazole compound of the general formula I, a pharmaceutically acceptable salt, enantiomer, diastereomer, racemate, atropisomer, polymorph, solvate, or isotopically labeled compound thereof:
wherein A is selected from-C (=O) (CH 2 ) x -、-C(=O)(CH 2 ) x NHC(=O)-、-(CH 2 ) x NHC(=O)(CH 2 ) y -、-(CH 2 ) x -、-(CH 2 CH 2 O) x (CH 2 ) y NHC(=O)CH 2 -、-(CH 2 ) x -B-C(=O)(CH 2 ) y -、-S(=O) 2 (CH 2 ) x NHC(=O)(CH 2 ) y -、-S(=O) 2 (CH 2 ) x NHC(=O)NH-;
x is independently selected from 0, 1, 2, 3, 4, 5, 6;
y is independently selected from 0, 1, 2;
b is a 4-8 membered heterocyclic ring containing 1, 2 or 3 heteroatoms selected from N, O, S; preferably a 4-6 membered heterocyclic ring, the heteroatom being N; more preferably the heterocycle is azetidine, azacyclopentane, azacyclohexane; more preferably B isWherein z is independently selected from 1, 2, 3; particularly preferred +.>
R is selected from C 1 -C 10 Alkyl, C 3 -C 10 Cycloalkyl, C 3 -C 10 Cycloalkyl oxy, C 6 -C 12 Aryl, 5-7 membered heteroaryl, the foregoing C 1 -C 10 Alkyl, C 3 -C 10 Cycloalkyl, C 3 -C 10 Cycloalkyl oxy, C 6 -C 12 Aryl, 5-7 membered heteroaryl groups may be substituted with one or more of the following groups: c (C) 1 -C 6 Alkyl, deuterium, halogen, cyano, nitro, amino, hydroxy, halogen substituted C 1 -C 6 Alkyl, hydroxy substituted C 1 -C 6 Alkyl, C 1 -C 6 Alkyloxy, halogen substituted C 1 -C 6 Alkyloxy, phenyl, -NH-Boc-, - (CH) 2 ) z -N=C(NH-Boc) 2 The heteroaryl contains 1, 2 or 3 heteroatoms selected from N, O, S, and z is 0, 1, 2 or 3; r is preferably selected from C 1 -C 6 Alkyl, C 3 -C 10 Cycloalkyl, C 3 -C 8 Cycloalkyl oxy, C 1 -C 6 Alkyl, C 3 -C 10 Cycloalkyl, C 3 -C 8 The cycloalkyloxy group may be substituted with one or more of the following groups: c (C) 1 -C 6 Alkyl, deuterium, halogen, cyano, nitro, amino, hydroxy, halogen substituted C 1 -C 6 Alkyl, hydroxy substituted C 1 -C 6 Alkyl, C 1 -C 6 Alkyloxy, halogen substituted C 1 -C 6 Alkyloxy, phenyl, -NH-Boc-, - (CH) 2 ) z -N=C(NH-Boc) 2 Z is 0, 1, 2 or 3; r is more preferably selected from C 1 -C 4 Alkyl, C 3 -C 10 Cycloalkyl, C 3 -C 6 Cycloalkyl oxy, C 1 -C 4 Alkyl, C 3 -C 10 Cycloalkyl, C 3 -C 6 The cycloalkyloxy group may be substituted with one or more of the following groups: c (C) 1 -C 4 Alkyl, deuterium, halogen, cyano, nitro, amino, hydroxy, halogen substituted C 1 -C 4 Alkyl, hydroxy substituted C 1 -C 4 Alkyl, C 1 -C 4 Alkyloxy, halogen substituted C 1 -C 4 Alkyloxy, phenyl, -NH-Boc-, - (CH) 2 ) 3 -N=C(NH-Boc) 2 The method comprises the steps of carrying out a first treatment on the surface of the R is more preferably selected from methyl, ethyl, n-methylPropyl, cyclopentyl, cyclohexyl, cycloheptyl, adamantyl, cyclopentyloxy, cyclohexyloxy, cycloheptyloxy, the foregoing methyl, ethyl, propyl, cyclopentyl, cyclohexyl, cycloheptyl, adamantyl, cyclopentyloxy, cyclohexyloxy, cycloheptyloxy may be substituted with one or more of the following groups: methyl, ethyl, n-propyl, isopropyl, deuterium, halogen, cyano, nitro, amino, hydroxy, phenyl, -NH-Boc-, - (CH) 2 ) 3 -N=C(NH-Boc) 2 The method comprises the steps of carrying out a first treatment on the surface of the More preferably, R is selected from adamantyl, cyclohexyloxy, triphenylmethyl, 2-triphenylethyl, unsubstituted or substituted with one or two members selected from the group consisting of methyl, isopropyl,further preferred, R is selected from adamantyl,/->Triphenylmethyl, 2-triphenylethyl, -, and->
2. The method of claim 1, wherein the oxazole compound, pharmaceutically acceptable salt, enantiomer, diastereomer, racemate, atropisomer, polymorph, solvate or isotopically labeled compound,
a is selected from-C (=O) (CH 2 ) x -、-C(=O)(CH 2 ) x NHC(=O)-、-(CH 2 ) x NHC(=O)(CH 2 ) y -、-(CH 2 ) x -、-(CH 2 CH 2 O) x (CH 2 ) y NHC(=O)CH 2 -、-(CH 2 ) x -B-C(=O)(CH 2 ) y -、-S(=O) 2 (CH 2 ) x NHC(=O)(CH 2 ) y -、-S(=O) 2 (CH 2 ) x NHC(=O)NH-;
x is independently selected from 0, 1, 2, 3, 4, 5, 6;
y is independently selected from 0, 1, 2;
b is 4-8 membered nitrogen heterocycle;
r is selected from C 1 -C 10 Alkyl, C 3 -C 10 Cycloalkyl, C 3 -C 10 Cycloalkyl oxy, C 1 -C 10 Alkyl, C 3 -C 10 Cycloalkyl, C 3 -C 10 The cycloalkyloxy group may be substituted with one or more of the following groups: c (C) 1 -C 6 Alkyl, deuterium, halogen, cyano, nitro, amino, hydroxy, halogen substituted C 1 -C 6 Alkyl, hydroxy substituted C 1 -C 6 Alkyl, C 1 -C 6 Alkyloxy, halogen substituted C 1 -C 6 Alkyloxy, phenyl, -NH-Boc, - (CH) 2 ) 3 -N=C(NH-Boc) 2 。
3. The method according to claim 1 or 2, wherein the oxazole compound, pharmaceutically acceptable salt, enantiomer, diastereomer, racemate, atropisomer, polymorph, solvate or isotopically labeled compound,
a is selected from-C (=O) (CH 2 ) x -、-C(=O)(CH 2 ) x NHC(=O)-、-(CH 2 ) x NHC(=O)(CH 2 ) y -、-(CH 2 ) x -、-(CH 2 CH 2 O) x (CH 2 ) y NHC(=O)CH 2 -、-(CH 2 ) x -B-C(=O)(CH 2 ) y -、-S(=O) 2 (CH 2 ) x NHC(=O)(CH 2 ) y -、-S(=O) 2 (CH 2 ) x NHC(=O)NH-;
x is independently selected from 0, 1, 2, 3, 4, 6;
y is independently selected from 0, 1, 2;
b is 4-8 membered nitrogen heterocycle;
r is selected from C 1 -C 10 Alkyl, C 3 -C 10 Cycloalkyl, C 3 -C 8 Cycloalkyl oxy, C 1 -C 10 Alkyl, C 3 -C 10 Cycloalkyl, C 3 -C 8 The cycloalkyloxy group may be substituted with one or more (e.g., 1, 2, or 3) of the following groups: c (C) 1 -C 6 Alkyl, phenyl, -NH-Boc, - (CH) 2 ) 3 -N=C(NH-Boc) 2 The method comprises the steps of carrying out a first treatment on the surface of the Preferably selected from C 1 -C 4 Alkyl, C 3 -C 10 Cycloalkyl, C 3 -C 8 Cycloalkyl oxy, C 1 -C 4 Alkyl, C 3 -C 10 Cycloalkyl, C 3 -C 8 The cycloalkyloxy group may be substituted with one or more of the following groups: c (C) 1 -C 4 Alkyl, phenyl, -NH-Boc- (CH) 2 ) 3 -N=C(NH-Boc) 2 。
4. The method according to claim 1 to 3, wherein the oxazole compound, pharmaceutically acceptable salt, enantiomer, diastereomer, racemate, atropisomer, polymorph, solvate or isotopically labeled compound,
a is selected from-C (=O) (CH 2 ) x -、-C(=O)(CH 2 ) x NHC(=O)-、-(CH 2 ) x NHC(=O)(CH 2 ) y -、-(CH 2 ) x -、-(CH 2 CH 2 O) x (CH 2 ) y NHC(=O)CH 2 -、-(CH 2 ) x -B-C(=O)(CH 2 ) y -、-S(=O) 2 (CH 2 ) x NHC(=O)(CH 2 ) y -、-S(=O) 2 (CH 2 ) x NHC(=O)NH-;
x is independently selected from 0, 1, 2, 3, 4, 5, 6;
y is independently selected from 0, 1, 2;
b is 6-membered nitrogen heterocyclyl;
r is selected from methyl, ethyl, n-propyl, cyclopentyl, cyclohexyl, cycloheptyl, adamantyl, cyclopentyloxy, cyclohexyloxy, cycloheptyloxy, the foregoing methyl groupsThe group, ethyl, n-propyl, cyclopentyl, cyclohexyl, cycloheptyl, adamantyl, cyclopentyloxy, cyclohexyloxy, cycloheptyloxy may be substituted with one or more of the following groups: methyl, ethyl, n-propyl, isopropyl, deuterium, halogen, cyano, nitro, amino, hydroxy, phenyl, -NH-Boc-, - (CH) 2 ) 3 -N=C(NH-Boc) 2 。
5. The method according to claim 1 to 4, wherein the oxazole compound, pharmaceutically acceptable salt, enantiomer, diastereomer, racemate, atropisomer, polymorph, solvate or isotopically labeled compound,
A is selected from-C (=O) CH 2 -、-C(=O)(CH 2 ) 2 -、-C(=O)CH 2 NHC(=O)-、-(CH 2 ) 2 NHC(=O)-、-(CH 2 ) 4 NHC(=O)CH 2 -、-(CH 2 ) 6 NHC(=O)-CH 2 -、-(CH 2 ) 2 NHC(=O)CH 2 -、-CH 2 -、-(CH 2 ) 2 -、-(CH 2 ) 3 -、-CH 2 CH 2 O-(CH 2 ) 2 NHC(=O)CH 2 -、-(CH 2 CH 2 O) 2 (CH 2 ) 2 NHC(=O)CH 2 -、-CH 2 -B-C(=O)CH 2 -、-S(=O) 2 (CH 2 ) 2 NHC(=O)CH 2 -、-S(=O) 2 (CH 2 ) 2 NHC(=O)NH-、-S(=O) 2 (CH 2 ) 2 NHC (=o) -; the other substituents are as defined above;
preferably, the method comprises the steps of,
a is selected from-C (=O) CH 2 -、-C(=O)(CH 2 ) 2 -、-C(=O)CH 2 NHC(=O)-、-(CH 2 ) 2 NHC(=O)-、-(CH 2 ) 4 NHC(=O)CH 2 -、-(CH 2 ) 6 NHC(=O)CH 2 -、-(CH 2 ) 2 NHC(=O)CH 2 -、-CH 2 -、-(CH 2 ) 2 -、-(CH 2 ) 3 -、-CH 2 CH 2 O-(CH 2 ) 2 NHC(=O)CH 2 -、-(CH 2 CH 2 O) 2 (CH 2 ) 2 NHC(=O)CH 2 -、-CH 2 -B-C(=O)CH 2 -、-S(=O) 2 (CH 2 ) 2 NHC(=O)CH 2 -、-S(=O) 2 (CH 2 ) 2 NHC(=O)NH-、-S(=O) 2 (CH 2 ) 2 NHC(=O)-;
B isWherein z is independently selected from 1, 2, 3; particularly preferred is +.>
R is selected from adamantyl, cyclohexyloxy, triphenylmethyl, 2-triphenylethyl, unsubstituted or substituted by one or two selected from methyl, isopropyl,further preferably, R is selected from adamantyl,triphenylmethyl, 2-triphenylethyl, -, and->
6. The oxazole compound of any of claims 1 to 5, pharmaceutically acceptable salts, enantiomers, diastereomers, racemates, atropisomers, polymorphs, solvates or isotopically labeled compounds thereof, wherein the oxazole compound is selected from the following structures:
wherein x, y, R are as defined previously and n is 1, 2, 3 or 4.
7. The oxazole compound of any of claims 1 to 6, pharmaceutically acceptable salts, enantiomers, diastereomers, racemates, atropisomers, polymorphs, solvates or isotopically labeled compounds thereof, wherein the oxazole compound is selected from the following structures:
8. A process for the preparation of an oxazole compound as claimed in any of claims 1 to 7 wherein the process is selected from one of the following:
the synthesis method comprises the following steps:
wherein R is defined in the respective claims;
step 1-1: the compounds 1A and 1B are activated by HATU and DIPEA in dimethylformamide solution at room temperature to generate a compound 1C through amidation reaction;
or alternatively, the first and second heat exchangers may be,
wherein R is defined in the respective claims;
step 1-2: reacting the compound 1D with trimethyl phosphorylacetate in tetrahydrofuran solution at 0-5 ℃ in the presence of sodium hydride to generate a compound 1E;
step 1-3: dissolving the compound 1E in methanol, adding sodium hydroxide aqueous solution, and hydrolyzing at 70 ℃ to generate a compound 1F;
step 1-4: the compound 1F is hydrogenated in methanol solution by Pd/C catalyst to obtain compound 1G;
step 1-5: the compound 1G and the compound 1A are activated by HATU and DIPEA in dimethylformamide solution at room temperature to generate a compound 1H through amidation reaction;
the synthesis method II comprises the following steps:
wherein R is defined in the respective claims;
step 2-1: the compound 2A, glycine methyl ester hydrochloride and triethylamine are activated in dimethylformamide solution at room temperature, and then are reacted to generate a compound 2B through EDCI and HOBt;
Step 2-2: dissolving the compound 2B in methanol, adding sodium hydroxide aqueous solution, and hydrolyzing at 70 ℃ to generate a compound 2C;
step 2-3: the compound 2C and the compound 1A are activated by HATU and DIPEA in dimethylformamide solution at room temperature to generate a compound 2D through amidation reaction;
and a synthesis method III:
wherein R is defined in the respective claims;
step 3-1: the compound 3A and 2, 2-diethoxyethyl-1-amine are activated by HATU and DIPEA in dimethylformamide solution at room temperature to generate a compound 3B through amidation reaction;
step 3-2: dissolving the compound 3B in acetonitrile, adding a 1N hydrochloric acid solution, and reacting at room temperature to obtain a compound 3C;
step 3-3: reacting the compound 3C with the compound 1A and triethylamine in a dichloromethane solution at room temperature in the presence of sodium triacetoxyborohydride to generate a compound 3D;
and a synthesis method:
wherein R is defined in the respective claims; n is taken from 0,1,2,3,4,5;
step 4-1: reducing the compound 4A into a compound 4B by lithium aluminum hydride in tetrahydrofuran solution at 0 ℃;
step 4-2: dissolving oxalyl chloride in tetrahydrofuran solution, cooling to-78 ℃, adding DMSO, reacting for a period of time, adding compound 4B, continuing to react, adding triethylamine in the later period of reaction, and heating to room temperature, and continuing to react to obtain compound 4C;
Step 4-3: reacting compound 4C with compound 1A and triethylamine in a dichloromethane solution in the presence of sodium triacetoxyborohydride at room temperature to produce 4D;
or alternatively, the first and second heat exchangers may be,
wherein R is defined in the respective claims; n is taken from 0,1,2,3,4,5;
step 4-4: adding concentrated sulfuric acid into a methanol solution of the compound 4A, and reacting at 80 ℃ to obtain a compound 4E;
step 4-5: compound 4E was reduced to compound 4B by lithium aluminum hydride in tetrahydrofuran solution at 0 ℃;
step 4-6: the compound 4B reacts with pyridine chlorochromate in dichloromethane solution at room temperature to obtain a compound 4C;
step 4-7: reacting compound 4C with compound 1A and triethylamine in a dichloromethane solution in the presence of sodium triacetoxyborohydride at room temperature to produce 4D;
the synthesis method is as follows:
wherein X is- (CH) 2 ) x -,-(CH 2 CH 2 O) x (CH 2 ) y -x, y, R are each as defined in the respective claims;
step 5-1: the compound 5A and the compound 5B are activated by HATU and DIPEA in dimethylformamide solution at room temperature to generate a compound 5C through amidation reaction;
step 5-2: adding triethylamine into a dichloromethane solution of the compound 5C, cooling to 0 ℃, dropwise adding a dichloromethane solution of methanesulfonic anhydride, and reacting at room temperature to generate a compound 5D;
Step 5-3: reacting the compound 5D with the compound 1A in a dimethylformamide solution at 80 ℃ in the presence of triethylamine to generate a compound 5E;
or alternatively, the first and second heat exchangers may be,
r is defined in the corresponding claims, n is selected from 0,1,2,3;
step 5-4: the compound 5A and the compound 5F are activated by HATU and DIPEA in dimethylformamide solution at room temperature to generate a compound 5G through amidation reaction;
step 5-5: adding triethylamine into a dichloromethane solution of the compound 5G, cooling to 0 ℃, dropwise adding a dichloromethane solution of methanesulfonic anhydride, and reacting at room temperature to generate a compound 5H;
step 5-6: reacting the compound 5H with the compound 1A in dimethylformamide solution at 80 ℃ in the presence of triethylamine to generate a compound 5I;
the synthesis method is six:
wherein R is defined in the respective claims;
step 6-1: the compound 1A and chloroethane-1-sulfonyl chloride react in methylene dichloride solution at the temperature of minus 40 ℃ in the presence of triethylamine to generate a compound 6A;
step 6-2: compound 6A is reacted in acetonitrile solution at room temperature in the presence of cesium carbonate and ammonium hydroxide to produce compound 6B;
Step 6-3: compound 6B and compound 6C are activated by HATU and DIPEA in dimethylformamide solution at room temperature to generate compound 6D through amidation reaction; or the compound 6B and the compound 6C are subjected to amidation reaction in acetonitrile solution in the presence of N-methylimidazole and tetramethyl chlorourea hexafluorophosphate to generate a compound 6D;
step 6-4: compound 6B and compound 6E were reacted in dichloromethane solution at room temperature to yield compound 6F.
9. A pharmaceutical composition comprising a compound of any one of claims 1-7, one or more of its pharmaceutically acceptable salts, enantiomers, diastereomers, atropisomers, racemates, polymorphs, solvates, or isotopically labeled compounds, and a pharmaceutically acceptable carrier, diluent, or excipient;
preferably, the pharmaceutical composition further comprises at least one additional therapeutic agent selected from the group consisting of an anticancer agent, an immunomodulator, an anti-inflammatory agent, an anti-alzheimer agent and combinations thereof.
10. Use of a compound according to any one of claims 1 to 8, a pharmaceutically acceptable salt, enantiomer, diastereomer, atropisomer, polymorph, solvate, isotopically-labeled compound or racemate thereof, or a pharmaceutical composition according to claim 9, for the manufacture of a medicament for the prevention and/or treatment of a disease or condition mediated by the CDK9-cyclin T1 complex;
Preferably, the disease or disorder mediated by the CDK9-cyclin T1 complex is selected from: breast cancer, osteosarcoma, endometrial tumor, leukemia, lung cancer, prostate cancer, melanoma, ovarian cancer, multiple myeloma, mesothelioma, gastric cancer, malignant rhabdoid tumor, hepatocellular carcinoma, biliary tract cancer, bladder cancer, brain tumor, neuroblastoma, schwannoma, glioma, glioblastoma, astrocytoma, endometrial cancer, esophageal cancer, head and neck cancer, pancreatic cancer, renal cell carcinoma.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210851738.3A CN117447466A (en) | 2022-07-19 | 2022-07-19 | Oxazole compound and preparation method and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210851738.3A CN117447466A (en) | 2022-07-19 | 2022-07-19 | Oxazole compound and preparation method and application thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117447466A true CN117447466A (en) | 2024-01-26 |
Family
ID=89584235
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210851738.3A Pending CN117447466A (en) | 2022-07-19 | 2022-07-19 | Oxazole compound and preparation method and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117447466A (en) |
-
2022
- 2022-07-19 CN CN202210851738.3A patent/CN117447466A/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230065463A1 (en) | Compounds and uses thereof | |
JP2022523073A (en) | Compounds and their use | |
CA2882496C (en) | Bivalent inhibitors of iap proteins and therapeutic methods using the same | |
WO2020160196A1 (en) | Compounds and uses thereof | |
EP3917517A1 (en) | Compounds and uses thereof | |
CN109071552A (en) | The degradation and application method that cell cycle protein dependent kinase 4/6 (CDK4/6) passes through the conjugation of CDK4/6 inhibitor and E3 ligase ligand | |
CN109153675A (en) | The degradation and application method that cell cycle protein dependent kinase 9 (CDK9) passes through the conjugation of CDK9 inhibitor and E3 ligase ligand | |
CA2865875C (en) | Piperidine compound or salt thereof | |
CN114057771B (en) | Macrocyclic compounds, their preparation and use | |
CN107922417B (en) | Use of pteridinone derivatives as EGFR inhibitors | |
AU2013366513A1 (en) | Novel benzimidazole derivatives as kinase inhibitors | |
WO2017071516A1 (en) | Kinase inhibitor, and preparing method and pharmaceutical use thereof | |
CN111989332B (en) | Macrocyclic compounds as CDK inhibitors, their preparation and their use in medicine | |
KR20220133259A (en) | Compounds and uses thereof | |
CN105884695B (en) | Heterocyclic derivatives species tyrosine kinase inhibitor | |
CA3224674A1 (en) | Tricyclic compounds as inhibitors of kras | |
CN114437116A (en) | Heterocyclic compound and preparation method, pharmaceutical composition and application thereof | |
CN117447466A (en) | Oxazole compound and preparation method and application thereof | |
WO2022236256A1 (en) | Heterocyclic compounds as kinase inhibitors | |
Wang et al. | Design, synthesis and anti-tumor efficacy of novel phenyl thiazole/triazole derivatives as selective TrkA inhibitors | |
CN114728994A (en) | Aryl phosphorus oxygen compound and application thereof | |
CN111205281A (en) | Heterocyclic compounds and their use | |
CN113773273B (en) | Benzisothiazole compound, preparation method and application thereof | |
JP2023536139A (en) | Compounds and uses thereof | |
US20210300939A1 (en) | Single Molecule Compounds Providing Multi-Target Inhibition of BTK and Other Proteins and Methods of Use Thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |